Review

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

Beatriz Ballester 1,2,*,†, Javier Milara 2,3,4,† and Julio Cortijo 1,2,5

1 Department of Pharmacology, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; julio.cortijo@uv.es
2 CIBERES, Health Institute Carlos III, 28029 Valencia, Spain; xmilara@hotmail.com
3 Pharmacy Unit, University Clinic Hospital of Valencia, 46010 Valencia, Spain
4 Institute of Health Research-INCLIVA, 46010 Valencia, Spain
5 Research and teaching Unit, University General Hospital Consortium, 46014 Valencia, Spain

* Correspondence: beaballester7@gmail.com; Tel.: +34-605148470
† These authors contributed equally to this work.

Received: 20 December 2018; Accepted: 28 January 2019; Published: 30 January 2019

Abstract: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2–4 years after diagnosis. A significant number of IPF patients have risk factors, such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer (LC) (mostly non-small cell lung cancer (NSCLC)). In fact, IPF itself increases the risk of LC development by 7% to 20%. In this regard, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with LC, such as myofibroblast/mesenchymal transition, myofibroblast activation and uncontrolled proliferation, endoplasmic reticulum stress, alterations of growth factors expression, oxidative stress, and large genetic and epigenetic variations that can predispose the patient to develop IPF and LC. The current approved IPF therapies, pirfenidone and nintedanib, are also active in LC. In fact, nintedanib is approved as a second line treatment in NSCLC, and pirfenidone has shown anti-neoplastic effects in preclinical studies. In this review, we focus on the current knowledge on the mechanisms implicated in the development of LC in patients with IPF as well as in current IPF and LC-IPF candidate therapies based on novel molecular advances.

Keywords: idiopathic pulmonary fibrosis (IPF); lung cancer (LC); non-small cell lung cancer (NSCLC)

1. Introduction

Idiopathic pulmonary fibrosis (IPF) is a form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults. IPF is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP) that is limited to the lungs [1]. The disease course of IPF is variable and somewhat unpredictable, nevertheless, progression to end-stage respiratory insufficiency and death after the onset of symptoms from diagnosis is 2–4 years [2]. Pulmonary and extrapulmonary comorbid conditions, such as lung cancer (LC), are commonly associated to IPF, altering the disease course and mortality. Links between pulmonary fibrosis and LC have been suggested as early as 1965 [3] and are based on the multiple common genetic, molecular, and cellular processes that connect both diseases and can predispose the patient to develop IPF and LC.

On its own, pulmonary fibrosis is a risk factor for developing lung carcinogenesis [4–7]. Moreover, elder age, male sex, history of smoking, and coexisting emphysema are also strong risk factors that contribute to developing LC in IPF patients [8–19]. The prevalence of LC in IPF patients ranges...
from 2.7% to 48% [8,9,13–20] (Table 1) and is significantly higher than in the general population [21]. Otherwise, the incidence of LC in IPF patients is reported to be 11.2–36 cases per 1,000 persons per year [8,20,22], which increases with each year following IPF diagnosis [15,18]. Moreover, IPF patients that are diagnosed with LC have a reduced mean survival time (1.6–1.7 years), compared to IPF patients without LC diagnosis [10,17] and Kato et al. reported 53.5%, 78.6%, and 92.9% as 1-, 3-, and 5-year all-cause mortality rates after LC diagnosis in IPF patients [8].

Table 1. Prevalence of lung cancer (LC) in idiopathic pulmonary fibrosis (IPF) patients.

| Study                  | Number of Patients with IPF | Prevalence of LC (%) | LC-IPF Male (%) | LC-IPF Median Age | LC-IPF Smokers (%) | Reference |
|------------------------|----------------------------|----------------------|-----------------|-------------------|--------------------|-----------|
| Nagai (1992)           | 99                         | 31.3%                | 87.1%           | 70.9              | 87.1%              | [9]       |
| Matsusitha (1995)      | 20                         | 48.2%                | 90%             | 66.4              | 74.3%              | [13]      |
| Park (2001)            | 281                        | 22.4%                | 97%             | 66.8              | 88.9%              | [14]      |
| Le Jeune (2007)        | 1064                       | 2.7%                 | ND              | ND                | ND                 | [20]      |
| Ozawa (2009)           | 103                        | 20.4%                | 95.2%           | 65.5              | 66.7%              | [15]      |
| Lee (2012)             | 1685                       | 6.8%                 | 94.7%           | 68.5              | 92.3%              | [16]      |
| Kreuter (2014)         | 265                        | 16%                  | ND              | ND                | ND                 | [17]      |
| Tomasetti (2015)       | 181                        | 13%                  | 82.6%           | 66.9              | 91.3%              | [18]      |
| Yoon (2018)            | 1108                       | 2.8%                 | 61%             | 65                | 77%                | [19]      |
| Kato (2018)            | 632                        | 11.1%                | 94.3%           | 66.8              | 100%               | [8]       |

ND: not determined.

2. Histological Subtypes and Parenchymal Distribution of Lung Cancer in Idiopathic Pulmonary Fibrosis

In the general population, the predominant type of LC is non-small cell lung cancer (NSCLC). Likewise, NSCLC is the predominant type of LC in LC-IPF patients. Furthermore, adenocarcinoma (ADC) is the most common subtype of histological NSCLC in the general population [23]. However, the most frequent histological subtype of LC in IPF has been controversial over the past few years (Table 2). Recently, the majority of studies have shown that squamous cell carcinoma (SQC) is the most frequent type of LC in IPF patients, while ADC is the second most frequent [8–10,14,15,17–19,24–29]. Moreover, some isolated cases of large cell carcinoma and small cell lung cancer (SCLC) have also been reported [8,14,18,27].

Table 2. Lung cancer (LC) histological subtypes in patients with idiopathic pulmonary fibrosis (IPF).

| Study         | Number of Patients with LC-IPF | Squamous Cell Carcinoma | Adenocarcinoma | Other Histological Subtypes | Reference |
|---------------|--------------------------------|-------------------------|----------------|-----------------------------|-----------|
| Kawai (1987)  | 8                              | 12.5%                   | 75%            | 12.5%                       | [24]      |
| Nagai (1992)  | 31                             | 45.2%                   | 35.2%          | 19.6%                       | [9]       |
| Park (2001)   | 63                             | 35%                     | 30%            | 35%                         | [14]      |
| Kawasaki (2001)| 53                             | 46%                     | 46%            | 8%                          | [25]      |
| Aubry (2002)  | 24                             | 67%                     | 29%            | 4%                          | [10]      |
| Ozawa (2009)  | 21                             | 38%                     | 29%            | 33%                         | [15]      |
| Saito (2011)  | 28                             | 67.9%                   | 25%            | 7.1%                        | [26]      |
| Lee (2014)    | 70                             | 40%                     | 30%            | 30%                         | [27]      |
| Kreuter (2015)| 42                             | 36%                     | 31%            | 33%                         | [17]      |
| Tomasetti (2015)| 23                             | 39%                     | 35%            | 26%                         | [18]      |
| Khan (2015)   | 34                             | 41%                     | 38%            | 21%                         | [28]      |
| Guyard (2017) | 18                             | 44%                     | 33%            | 23%                         | [29]      |
| Yoon (2018)   | 27                             | 41%                     | 26%            | 33%                         | [19]      |
| Kato (2018)   | 70                             | 30%                     | 20%            | 50%                         | [8]       |

Similarly to fibrotic lesions, lung carcinomas are generally more frequently found in the peripheral area of the lungs in IPF patients, i.e., in the lower lobes [3,8,16,25,30–32], and are associated with honeycomb lesions, developing from honeycomb areas or in the border between honeycombing and
non-fibrotic areas, and epithelial metaplasia [33–35]. In general, squamous metaplasia, but not cuboidal cell metaplasia or bronchial cell metaplasia, have been observed more frequently in LC-IPF patients than in IPF patients without lung carcinoma. Then, it is speculated that it might reflect a constitutional susceptibility of IPF patients of developing lung carcinoma [36].

3. Cell Types and Cellular Processes Involved in Lung Cancer Associated with Pulmonary Fibrosis

3.1. Cell Transformations in the Mesenchymal Phenotype

IPF is characterised by an excess of myofibroblasts that are persistently activated in fibrotic lungs [37]. The activated myofibroblasts are stellate- or spindle-shaped, and are characterised by the secretion of extracellular matrix (ECM) components (a characteristic shared with fibroblasts), such as collagen type I, and by the formation of contractile apparatus (a characteristic shared with airway smooth muscle cells), such as α-smooth muscle actin (α-SMA) microfilaments [38]. In IPF lungs, myofibroblasts have heterogeneous phenotypes [39] (Figure 1). The classic concept is that tissue injury induces the activation of resident fibroblasts to proliferate and express constituents of the ECM and α-SMA fibres [40]. One contemporary theory is that tissue injury in the presence of transforming growth factor (TGF-β) induces epithelial to mesenchymal cell transition (EMT) [41,42]. In detail, EMT is part of an unabated form of wound healing in which alveolar type II (ATII) cells [41–43] can serve as a source for the increased myofibroblast-like pool that eventually leads to organ destruction if the primary inflammatory insult that triggered the wound healing is not removed or attenuated [44]. Another contemporary theory of myofibroblast activation is that circulating fibrocytes that originate from the bone marrow are mesenchymal progenitor cells that home and extravasate into sites of tissue injury, and differentiate into the myofibroblast-like phenotype [45,46] in response to TGF-β and endothelin 1 [47–49]. Pulmonary arterial endothelial cell to mesenchymal transition (EnMT) has been suggested as another source of myofibroblasts that potentially contribute to lung fibrosis and pulmonary hypertension and is often associated with IPF, which portends a poor prognosis [50,51]. Finally, there are two emerging theories that consider pleural mesothelial cells or lung pericytes as significant sources of lung myofibroblasts in IPF [52–56].

Similarly to IPF, cancer-associated fibroblasts (CAFs) are also important players in LC because they exhibit mesenchymal-like features and have heterogeneous phenotypes (Figure 1) [57]. Lung resident fibroblasts surrounding the malignancy are thought to be the first responders to the site of insult that the tumour creates [58]. Resident epithelial cells—generally bronchiolar epithelial cells—can also undergo a partial and possibly reversible EMT during the early steps of carcinogenesis, cancer invasion, and metastasis [44,59]. Likewise, fibrocytes recruited from the peripheral circulation have also been suggested as a potential source of CAFs [58,60,61]. It has also been observed that up to 40% of CAFs arise as a consequence of EndMT in two different murine cancer models, suggesting that EndMT may play a role in tumour angiogenic sprouting into adjacent tissue [62]. In the tumour environment, vascular pericytes have also been associated with tumour vasculature. Pericytes that detach from the tumour microvasculature have been shown to undergo differentiation into stromal fibroblasts via the action of platelet-derived growth factor-BB (PDGF-BB), which significantly contributes to tumour invasion and metastasis [63]. Finally, pleural mesothelial cells are also hypothesised as a source of CAFs, where a mesothelial precursor lineage has been identified as being capable of clonally generating fibroblasts in the lungs, kidney, liver, and gut [64]. Also, it has been reported that an overexpression of mesothelin in lung ADC is induced by tobacco-related carcinogens [57].
3.2. Common Cellular Processes in Lung Cancer Associated with Pulmonary Fibrosis

3.2.1. Apoptosis and Autophagy

Growing evidence indicates a prominent role of enhanced endoplasmic reticulum (ER) stress in IPF, resulting in an unfolded protein response (UPR) \[65,66\]. This response mechanism activates biochemical pathways to meet the demands of protein folding. However, if that is no longer feasible, a terminal UPR directs alveolar epithelium cells towards apoptosis. By contrast, IPF myofibroblasts and cancer cells escape apoptosis \[67,68\]. Regarding the role of ER-stress in tumourigenesis, it is controversial \[69,70\], nevertheless, recent evidence shows that ER stress may attenuate senescence and promote tumorigenesis \[71\] (Figure 1).

Despite elevated ER stress, there is evidence that autophagy is defective in IPF \[72–74\] (Figure 1), which promotes lung fibroblast differentiation into myofibroblasts via excessive ECM production \[72,74,75\] and fibroblast resistance to apoptosis \[76\]. In LC, autophagy functions as a double-edged sword because it suppresses tumorigenesis in a limited number of contexts while facilitating it in most others \[77\]. In fact, it has been observed that autophagy can promote or inhibit apoptosis under different cellular contexts within the same tumour cell population. Therefore, therapeutic targeting of autophagy in cancer is sometimes viewed as controversial \[78\].

3.2.2. Cellular Proliferation

Evidence strongly supports the persistent activation of proliferative signalling pathways in IPF (Figure 1). In fact, myofibroblasts sustain their own growth through the autocrine production of TGFβ1 and partly lose their ability to produce anti-fibrotic prostaglandin E2 (PGE2) \[79\]. Further, they show a lack of response to the inhibitory activity of PGE2 \[80\], and to other antiproliferative signals \[81\].
The receptors for platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF) have also recently been implicated in the sustained proliferation signalling of pulmonary fibroblasts [82]. However, this persistent activation is not definitively linked with aberrant fibroblast proliferation in vivo [83–85] and the role of excessive fibroblast proliferation as a pathogenic mechanism of IPF is unclear. By contrast, aberrant proliferation of cancer cells and sustained proliferative signalling has been described as “arguably the most fundamental trait of cancer cells” [68].

3.2.3. Altered Cell-Cell Communications

Intercellular channels that are formed by connexins are essential for the synchronisation of cell proliferation and tissue repair [86]. In particular, the expression of connexin 43 (Cx43) is considered crucial in fibroblast-to-fibroblast communication. In IPF fibroblasts, Cx43 expression is strongly down-regulated, leading to a loss of proliferative control [87]. Similarly, cancer cell lines from mouse and human lung carcinoma have low levels or an absence of Cx43 expression [88], which results in reduced cell-to-cell communication (Figure 1); this may explain both the release of cells from contact-inhibition control, and the uncontrolled proliferation that characterises this disease.

3.2.4. Senescence

Analyses of cell types in the lungs of both human IPF and the bleomycin-injured mouse model have demonstrated that fibroblasts and epithelial cells acquire senescent identities [89]. Senescence appears to be a central phenotype that promotes lung fibrosis through increased production of a complex senescence-associated secretory phenotype (SASP) based on growth factors, cytokines, chemokines, and matrix metalloproteinases, as well as acquired apoptosis resistance in IPF fibroblasts [90] (Figure 1). However, therapeutic management of cell senescence is controversial in cancer. On the one hand, cell senescence could limit the replicative capacity of cells and ultimately prevent their proliferation in different stages of malignancy, while providing a protective barrier to neoplastic expansion [91]. On the other hand, it has been proposed that senescent fibroblasts may promote tumour progression, possibly by secreting an SASP based on certain matrix metalloproteases, growth factors, and cytokines [92].

3.2.5. Tissue Invasion

IPF lung fibroblasts are characterised by their ability to invade through the basement membrane and the ECM via the action of metalloproteinases [93,94]. This characteristic is also an important hallmark of cancer (Figure 1). Unlike cancers that can disseminate over long distances because they acquire further invasive mechanisms, fibrotic lung fibroblasts are restricted to local invasion [95]. The capacity of cancer cells to infiltrate the surrounding tissue is strictly related to the expression of laminin, heat shock protein 27, and fascin [96–98]. Interestingly, in IPF, it has been shown that bronchiolar basal cells surrounding the fibroblast foci express large amounts of these proteins, which induce cell motility and invasiveness of myofibroblasts [99]. Therefore, targeting these molecules may be a feasible strategy to restrain myofibroblast tissue invasion in LC-IPF patients.

3.2.6. Inflammation

The role of inflammation in IPF is controversial, although evidence shows the existence of a predominant phenotype of fibrosis-associated macrophages (FAMs) that are alternatively activated. These are an M2 phenotype of FAMs [100] that facilitate the enhanced production of FGFs [101], profibrotic cytokines [102,103], and matrix metalloproteinases [104]. Like FAMs, tumour-associated macrophages also display an M2 phenotype and support tumour growth through their ability to promote angiogenesis, activate mesenchymal cells, remodel the matrix, and suppress effector T-cell responses [105,106]. Thus, M2 macrophages could be considered key effectors in the development of LC associated with pulmonary fibrosis.
4. Principal Fibrogenic Molecules and Signal Transduction Pathways Participating in Lung Cancer Associated with Pulmonary Fibrosis

4.1. Growth Factors

TGFβ is a major profibrotic growth factor and is often chronically overexpressed in cancer and fibrosis (Table 3) [107]. TGFβ can be activated by αVβ6 integrin and, in IPF, TGFβ1 mediates fibrogenesis by antiproliferative action and apoptosis in alveolar epithelial cells (AECs) or by stimulation of fibroblast differentiation to myofibroblasts, synthesis of ECM proteins, and inhibition of ECM degradation [108,109]. TGFβ also induces the production of fibrogenic or angiogenic growth factors and is known to strongly elicit EMT and EndMT. In the early stages of cancer pathogenesis, TGFβ acts as a tumour suppressor because it inhibits the growth of many cell types and delays the appearance of primary tumors. However, after the appearance of them, TGFβ promotes tumour progression, because it can induce EMT and EndMT, and suppresses immune surveillance. Therefore, during tumour progression, TGFβ triggers the formation of spontaneous lung metastases. Finally, TGFβ is also central in the development of the tumour stroma because TGFβ1 also activates CAFs [107,110].

Tyrosine kinase receptor ligands, such as PDGF, VEGF, and FGF, are aberrantly expressed in LC and IPF (Table 3) [82]. In IPF, PDGF plays an important role in inducing the secretion of ECM components and growth factors in fibroblasts [111]. It also promotes fibroblast proliferation and recruits fibrocytes to the lung [112,113]. Furthermore, TGFβ1, FGF, and tumour necrosis factor-α exhibit PDGF-dependent profibrotic activity [114,115]. Otherwise, PDGF signalling is also important for tumour growth, angiogenesis, and lymphangiogenesis in cancer [113]. In fact, it has been shown that crenolanib (PDGF receptor inhibitor) is capable of suppressing proliferation and inducing apoptosis in a dose-dependent manner using A549 cells as a NSCLC model system. Moreover, it has been shown that crenolanib-treated A549 cells have reduced migratory activity in response to inducers of chemotaxis, and the antitumor activity of this drug has been confirmed in an NSCLC xenograft tumor model [116]. Finally, it has been observed that PDGF regulates VEGF expression in NSCLC via an autocrine mechanism [117], and is also involved in the recruitment of CAFs to the tumour mass [113].

The contribution of VEGF to IPF is not fully understood because there is still debate on the role of vascular remodelling in IPF [118]. However, in addition to the role of VEGF in tumour angiogenesis, accumulating evidence suggests that it can act directly on cancer cells to regulate growth, migration, and production of several pro-angiogenic factors [119]. FGF is also released by damaged epithelial cells and activated fibroblasts during the remodelling processes [120,121]. It was found that FGF signalling is required for fibroblast expansion within fibrotic areas [122]. FGF can also affect the proliferation, treatment sensitivity, and apoptosis of LC cells [123].

Another important fibrogenic growth factor in LC is connective tissue growth factor (CTGF). In IPF, CTGF induces fibroblast proliferation and ECM deposition [124]. By contrast, it has been observed that CTGF inhibits metastasis and invasion of human lung ADC [125], and its expression is suppressed in many NSCLCs [126] (Table 3).

Several other growth factors are involved in IPF and LC [127–129], but we have not included them in this review because they are not the focus of the new therapies currently being developed.

4.2. LysoPhosphatidic Acid (LPA)

LPA, a profibrotic mediator with proinflammatory activity, is released by platelets during epithelial injury [130]. Extracellular production of LPA is catalysed by autotaxin (ATX) and further regulated by phospholipid phosphatases (PLPP). IPF patients have increased LPA levels [131] in their bronchoalveolar lavage fluid (BALF) (Table 3), and recently, it has been shown that LPA signalling mediates both the fibroblast recruitment and vascular leakage induced by lung injury in a bleomycin model of pulmonary fibrosis [131]. Moreover, it has recently been shown that the ATX/PLPP3-LPA/LPA receptor 1 (LPAR1) axis has a procarcinogenic role in lung carcinogenesis [132].
Table 3. Principal fibrogenic molecules and signal transduction pathways participating in lung cancer (LC) and idiopathic pulmonary fibrosis (IPF).

|                          | IPF                  | LC                   |
|--------------------------|----------------------|----------------------|
| **Growth Factors**       |                      |                      |
| TGFβ1                    | Overexpressed        | Overexpressed        |
| PDGF                     | Overexpressed        | Overexpressed        |
| VEGF                     | Overexpressed        | Overexpressed        |
| FGF                      | Overexpressed        | Overexpressed        |
| CTGF                     | Overexpressed        | Downregulated        |
| **Profibrotic mediators**|                      |                      |
| LPA                      | Overexpressed        | Overexpressed        |
| Galectin-3               | Overexpressed        | Overexpressed        |
| **Cytokines**            |                      |                      |
| CCL2                     | Overexpressed        | Overexpressed        |
| IL-13                    | Overexpressed        | Overexpressed        |
| **Mucins**               |                      |                      |
| Mucin 1                  | Overexpressed        | Overexpressed        |
| Mucin 4                  | Overexpressed        | Overexpressed        |
| Mucin 5B                 | Overexpressed        | Overexpressed        |
| **Embryological pathways**|                     |                      |
| Wnt pathway              | Overexpressed        | Overexpressed        |
| Shh pathway              | Overexpressed        | Overexpressed        |
| Notch pathway            | Overexpressed        | Overexpressed        |
| **Proliferation-related pathways**|               |                      |
| PI3K/AKT/mTOR pathway    | Overexpressed        | Overexpressed        |
| **Migration-related proteins**|                  |                      |
| Laminin                  | Overexpressed        | Overexpressed        |
| Fascin                   | Overexpressed        | Overexpressed        |
| Hsp27                    | Overexpressed        | Overexpressed        |
| **Oxidative stress-related molecules**|             |                      |
| NOX4                     | Overexpressed        | Overexpressed        |
| Nrf2                     | Downregulated        | Downregulated        |
| **Cell-cell communication-related proteins**|                          |                      |
| Connexin 43              | Downregulated        | Downregulated        |

TGFβ1: transforming growth factor β1; PDGF: platelet derived growth factor; VEGF: vascular endothelial growth factor; FGF: fibroblast growth factor; CTGF: connective tissue growth factor; LPA: lysophosphatidic acid; CCL2: chemokine ligand 2; IL-13: interleukin 13; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B; mTOR: mammalian Target of Rapamycin; Hsp27: heat shock protein 27; NOX4: NADPH oxidase 4.

4.3. Cytokines and Chemokines

Epithelial injury causes an imbalance in T-helper type 1 (Th1)/type 2 (Th2) cytokine expression, which results in a stronger Th2 response. In particular, there is evidence that interleukin 13 (IL-13) [133] plays a dominant role in the pathogenesis of fibrosis in the lungs of IPF patients (Table 3) [134]. IL-13 triggers the transformation of fibroblasts to myofibroblasts via the TGFβ-dependent and -independent pathways, while also inducing epithelial apoptosis [135–137]. Similarly to IPF, a pattern of Th2 cytokine expression has also been identified in NSCLC [138]. With respect to IL-13, a recent study observed the highest expression level of IL-13 in LC in the SQC subtype, followed by the ADC subtype [139]. Moreover, a clear association between IL-13 receptor subunit alpha-2 overexpression and poor survival in resected NSCLC patients has been shown [140]. There are other profibrotic cytokines besides IL-13 that are also associated with IPF. For example, chemokine ligand 2 (CCL2) has been reported to be present in the BALF of IPF patients at significant concentrations [141] (Table 3). In IPF, CCL2 has been shown to induce the differentiation of developing T-cells into type 2 cells [142], and to stimulate collagen synthesis and TGFβ expression in lung fibroblasts [141]. In LC, the CCL2/CCR2 (chemokine...
receptor type 2) axis is also important in several aspects of tumorigenesis. One of its most important roles is the generation of new vascular structures that allow tumour growth [140]. However, there is evidence of an association between CCL2 in cancer cells and better survival in NSCLC patients [143].

4.4. Reactive Oxygen Species (ROS)

ROS production by ATII cells results in oxidative stress, which induces apoptosis of epithelial cells, activates intracellular signalling pathways, and upregulates the synthesis of profibrotic cytokines that ultimately leads to tissue injury and fibrosis [144]. In this context, upregulation of NADPH oxidase 4 (NOX4) has been reported in pulmonary fibroblasts and other relevant cells in IPF. In the same way, NOX4 has been reported to be overexpressed in NSCLC (Table 3), contributing to cell proliferation and metastasis [145]. Furthermore, following ROS overproduction, alterations in DNA methylation patterns and specific histone modifications lead to aberrant gene expression, and possibly trigger the multistage process of carcinogenesis [144]. In addition, antioxidant molecules that mitigate oxidative stress, such as Nrf2, have also been reported to be dysregulated in both diseases [146,147] (Table 3). As such, they are proposed to be future targets for anti-IPF/LC treatment.

4.5. Mucins

Significant overexpression of the secreted Mucin 5B (Muc5B) protein has been found in IPF lungs (Table 3) and it is hypothesised that excess Muc5B impairs the mucosal host defence; in turn, this may interfere with alveolar repair and leads to the development of idiopathic interstitial pneumonia [148]. In this context, MUC5B expression has been associated with a high risk of distant metastasis in NSCLC patients and poorer prognosis in ADC patients [149,150].

We have also observed IPF overexpression of the transmembrane mucins, Muc1 [151], Muc4 [152], and Muc16 (unpublished data), which may be involved in the molecular processes that lead to the development of pulmonary fibrosis [151–153]. In addition, the extracellular region of Muc1 contains the KL-6 epitope, which is proposed to be a useful biomarker for evaluating disease activity and predicting clinical outcomes in IPF [154]. Similarly, these transmembrane mucins have previously been considered clinically relevant proteins that are aberrantly overexpressed in lung carcinogenesis [155]. In fact, Muc1 is a target in several preclinical and clinical trials for cancer treatment [156,157]. Concurrently, there is evidence that galectin 3 is a promising target for IPF [158] because it has a profibrotic action [159] that is partly mediated by binding to Muc1 [160]. Recently, the potential of galectin-3 as a therapeutic target in cancer has been highlighted since it is capable of modulating anti-tumour immunity [161].

4.6. Embryological Pathways

There is also evidence that some embryological pathways are reactivated or deregulated in fibrotic diseases (Table 3) [162]. For example, the Wnt/β-catenin pathway is overexpressed in the lung tissue of IPF [163] and LC patients [164]. This pathway regulates the expression of molecules involved in tissue invasion, such as matrixisin, laminin, and cyclin-D1, which induces the EMT process. Most importantly, this pathway is involved in biologically relevant cross talk with TGF-β [163].

The Sonic hedgehog (shh) pathway is also aberrantly activated in IPF, mainly in epithelial cells that line honeycomb cysts [165,166]. The overexpression of the shh pathway promotes increased susceptibility to epithelial cell apoptosis and increased resistance to fibroblast apoptosis [167]. This pathway is also reactivated at the early stage of oncogenesis by cancer stem cells and leads to paracrine action on other tumour cells, resulting in tumour growth, tumour spread, and EMT. In LC, reactivation of the shh pathway is involved in the development of resistance to all the main treatments of LC [168].

Finally, the Notch signalling pathway is also reactivated in AECs, induces α-SMA expression in fibroblasts, and mediates EMT in AECs [52]. In the same way, abnormal expression of the members of the Notch signalling pathway is a relatively frequent event in patients with NSCLC [169,170]. It has been demonstrated that members of the Notch signalling pathway may be potential biomarkers for
predicting the progression and prognosis of patients with NSCLC. Furthermore, Notch signalling promotes the proliferation of NSCLC cells or inhibits apoptosis of NSCLC cells [171].

4.7. PI3K/AKT/mTOR Pathway

The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)-dependent pathway is dysregulated in fibroproliferative diseases, like pulmonary fibrosis (Table 3) [172]. In fact, overexpression of class I isoform p110γ in lung homogenates occurs in IPF patients [173], and has been shown to activate the downstream signalling of several key profibrotic growth factors implicated in IPF, including PDGF and TGFβ1 [174,175], as well as abnormal proliferation of epithelial basal cells [173] and TGF-β-induced fibroblast proliferation and differentiation [176]. Moreover, it has been observed that the suppression of phosphatase and tensin homologue mediates matrix-mediated resistance to apoptosis [174]. Phosphatase and tensin homologue are negative regulators of PI3K that in turn activate AKT. De-regulation of the PI3K/AKT/mTOR pathway is also involved in NSCLC and has been associated with high grade tumours and advanced disease. Furthermore, abnormalities in this pathway are more common in SQC than in ADC of the lung [177].

5. Genetic and Epigenetic Alterations in Lung Cancer Associated with Pulmonary Fibrosis

5.1. Genetic Alterations

Most pulmonary fibrosis patients who have a background of familial clustering of familial interstitial pneumonia show mutations in genes that encode surfactant-associated protein C (SFTPC) [178,179], surfactant-associated protein A2 (SFTP A2) [180], telomerase components (TERT and TERC) [181,182], and genes associated with telomere biology, such as poly (a)-specific ribonuclease deadenylation nuclease (PARN) and regulator of telomere elongation helicase 1 (RTEL1) [183]. Further, several common variants in TERT, genomic regions near TERC, oligonucleotide-binding fold containing 1 (OBFC1), RTEL1, PARN, and toll-interacting protein (TOLLIP), have all been associated with a sporadic risk of developing IPF [184–186]. Nevertheless, the most important genetic risk factor for sporadic IPF is a common variant (rs35705950) in the promoter region of the MUC5B gene, although it is also associated with familial pulmonary fibrosis [148] (Table 4).

LC development is the result of a stepwise accumulation of multiple acquired mutations of tumour suppressor genes or candidates, and the overexpression and mutation of oncogenes (Table 4). In this context, multiple P53 gene mutations have been found during the early stage of bronchial carcinoma [187,188]. Frequent P53 gene alterations have also been detected in epithelial lesions from IPF patients [189] and in squamous metaplasia, distributed in the peripheral zone of the fibrotic area in patients with IPF [190]. Similarly, aberration and loss of function of the candidate tumour suppressor gene fragile histidine triad (FHIT) has been reported in NSCLC [191], as well as in IPF lesions [192]. Additionally, FHIT gene allelic loss has been seen more frequently among the metaplasias and bronchiolar epithelia samples obtained from LC-IPF patients than from IPF patients without LC [192]. Otherwise, the frequency of expression of Ras protein in ATII cells has been observed as being significantly greater in lung tissues from LC-IPF patients compared with lung tissues from IPF patients who did not have lung carcinoma. Moreover, a specific point mutation in codon 12 of the KRAS gene has been detected in LC-IPF patients [189]. Interestingly, this mutation has not been identified between the numerous KRAS mutations observed in lung carcinoma tissue [193]. However, contrasting results regarding the prevalence of KRAS mutations in LC-IPF patients have been reported recently [194,195]. In addition, a significantly higher prevalence of BRAF mutations in IPF-LC than in LC has been observed, with an equal distribution between ADC and SQC subtypes. Moreover, some of these somatic mutations have not been shown to be significant in NSCLC patients [195]. As such, it is rational to suggest that these somatic mutations in tumour suppressor genes and oncogenes, as well as oncogene overexpression, predispose IPF patients to develop LC. However, it also raises
two controversial questions: Why is LC not the cause, instead of a consequence, of IPF?; and why do LC and IPF not independently and synchronously develop as a result of common pathogenetic mechanisms? In answering these questions, Hwan et al. [195] revealed a predominance of C>T somatic transitions in most of the somatic mutations detected in LC-IPF patients. By contrast, in the non-IPF SQC subtype, C>A transversions are the most frequent [196]. This suggests a potential association between APOBEC (cytidine deaminase, which converts cytosine to uracil)-related mutagenesis and the development of LC associated with pulmonary fibrosis.

Recently, germline mutations associated with familial NSCLC and predisposing to it are also being discovered [197] (Table 4). In this context, several findings suggest that some germline mutations that predispose patients to develop IPF also predispose them to developing lung carcinoma. Indeed, two heterozygous missense mutations, and a heterozygous missense mutation in SFTP A2 [198] and SFTP A1 [199], respectively, have been identified in LC-IPF families. All of these mutations are predicted to disrupt the structure of surfactant A protein (SP-A) and impair protein secretion [198,199], leading to protein instability and ER stress of resident ATII cells [179,200]. SP-A is produced by ATII and club cells [201], which have both been proposed as possible initiators of lung ADC [202]. Although the role of ER-stress in tumourigenesis is controversial [69,70], recent evidence showing that ER stress may attenuate senescence and promote tumorigenesis might explain the co-occurrence of LC (histological subtype ADC) and pulmonary fibrosis in families with an SFTP A1/2 mutation [71]. Two further germline mutations in TERT (rs2736100) and CDKN1A (rs2395655), which were previously reported to confer IPF risk [203], have also been identified in several LC-IPF patients [195]. These mutations affect telomerase function and impair the cellular response to DNA damage, respectively [204]. Accordingly, they might also explain the co-occurrence of both diseases. Furthermore, the germline variant, rs2736100, has been reported to be associated with lung ADC risk [205], and other TERT, TERC, OFBC1, and RTEL1 polymorphisms have also been revealed as risk factors of LC [206,207]. However, telomere functionality and its contribution to LC development is controversial. In fact, a gain at chromosomal region 5p15.33 in TERT is the most frequent genetic event in the early stages of NSCLC [208]. However, short telomeres in peripheral blood leukocytes have been related to an increased risk of lung carcinoma [209], probably via an increased mutation rate and the genomic instability induced by telomere dysfunction [210]. Therefore, it might be hypothesised that mutations associated with telomere biology in IPF lesions, which correlate with shortened telomeres in leukocytes and ATII cells [211], could drive the development of LC via an increased mutation rate and genomic instability.

Finally, the germline or somatic variant (rs35705950) in the MUC5B promoter region that consists of TT and GT genotypes (risk genotypes for IPF) has been reported to confer a survival advantage among patients with IPF [212]. However, these genotypes are associated with poorer overall survival in NSCLC patients [213]. Furthermore, significant associations between the MUC5B promoter polymorphism and the incidence of radiation pneumonitis in patients with NSCLC have not been identified [213]. This supports the idea that IPF underlies the development of LC and is not a consequence of it.

5.2. Epigenetic Alterations

Due to similar pathogenic mechanisms between IPF and LC, their global methylation patterns are also somewhat similar (Table 4). However, there are also differences, which may be explained partly by IPF or cancer-specific changes [214]. For example, it was found that as a consequence of promoter hypermethylation, the relative expression of the SMAD4 gene was significantly lower in the tumours of LC-IPF patients compared to those who had LC without IPF [215]. This was a surprising finding because SMAD4 has been identified as a tumour-suppressor gene [216], but TGFβ1 signalling is the main effector in pulmonary fibrosis. Thus, SMAD4 over-expression would be expected in this disease. Another epigenetic alteration involved in IPF is THY-1 promoter hypermethylation and the absence of fibroblast Thy-1 expression, which is linked to the transformation of fibroblasts into myofibroblasts [217]. Loss of this molecule has also been documented in cancer and is associated with a more invasive disease [218]. By contrast, promoter hypermethylation of the O-6-methylguanine
DNA methyltransferase (MGMT) gene is one of the early epigenetic marks in LC [219], while in IPF fibroblasts, MGMT is one of the most hypomethylated genes [220].

Otherwise, ~10% of miRNAs are abnormally expressed in IPF [95]. These variations are all capable of influencing EMT and inducing the regulation of apoptosis or ECM [95]. Some of these variations are also found in LC. For example, common to IPF, mir-21 is overexpressed in IPF and LC and acts as an oncogene [95,219,222].

Table 4. Mutated genes, hypermethylated genes, and non-coding RNAs with altered expression in Idiopathic pulmonary fibrosis (IPF), lung cancer (LC), and LC-IPF patients.

| Mutated Genes | IPF | LC | LC-IPF |
|---------------|-----|----|--------|
| SFTPA1        | Yes [199] | ND | Yes [199] |
| SFTPA2        | Yes [180] | ND | Yes [198] |
| TERT          | Yes [181,184] | Yes [206,207] | Yes [195] |
| TERC          | Yes [181,184] | Yes [206,207] | ND |
| PARN          | Yes [183] | ND | ND |
| OBFC1         | Yes [184] | Yes [207] | ND |
| RETL1         | Yes [183] | Yes [207] | ND |
| TOLLIP        | Yes [186] | ND | ND |
| MUC5B         | Yes [148] | Yes [213] | ND |
| PS3           | Yes [189] | Yes [187,188] | Yes [190] |
| FHIT          | Yes [192] | Yes [191] | Yes [192] |
| KRAS          | ND | Yes [193] | Yes [194] |
| BRAF          | ND | Yes [223] | Yes [195] |
| CDKN1A        | Yes [203] | ND | Yes [195] |

| Hypermethylated Genes | IPF | LC | LC-IPF |
|-----------------------|-----|----|--------|
| SMAD4                 | ND | ND | Yes [215] |
| THY-1                 | Yes [217] | ND * | ND |
| MGMT                  | No [220] | Yes [219] | ND |

| Non-coding RNAs | IPF | LC | LC-IPF |
|-----------------|-----|----|--------|
| Let-7d          | Downregulated [95] | Downregulated [219] | ND |
| mir-21          | Upregulated [95] | Upregulated [221] | ND |

ND: Not determined. * Reported in metastatic nasopharyngeal carcinoma [218].

6. Therapeutic Management in Lung Cancer Associated with Pulmonary Fibrosis Patients

The focus of IPF treatment in previous decades has been to use anti-inflammatory/immunomodulatory drugs in combination with antioxidants. However, their therapeutic usefulness was recently questioned given the unfavourable outcome when N-acetyl L-cysteine (NAC) was used in combination with prednisolone/azathioprine [224]. Following this, NAC monotherapy results were also negative [225], although a subgroup of IPF patients with the rs3750920 (TOLLIP) TT genotype showed a favourable response [226]. Numerous cellular and preclinical studies hold that antioxidants protect against cancer [227,228]. However, it has been shown that NAC increases tumour progression and reduces survival in LC preclinical models [229], which contraindicates NAC treatment for LC-IPF.

In line with the antioxidant treatments tested in IPF, pirfenidone was initially considered as an antioxidant therapy since it demonstrated O$_2^-$ scavenging activity [230,231]. Oral NAC has been used in conjunction with pirfenidone to treat IPF, but it does not substantially alter the tolerability profile of pirfenidone and is unlikely to be beneficial in IPF [232]. Beyond its antioxidant activity, pirfenidone is a pleiotropic molecule that inhibits TGF-β, collagen synthesis, and fibroblast proliferation, and also mediates tissue repair [233–236]. It is currently approved as an IPF therapy and Miuri et al. [237] observed that the incidence of LC in IPF patients treated with pirfenidone was significantly lower than
in a non-pirfenidone IPF patient group. Furthermore, recent publications have shown that pirfenidone confers anti-fibrotic effects by interfering with the shh pathway [238], which can partly explain the observed lower LC incidence in IPF patients treated with pirfenidone. It has also been observed that perioperative pirfenidone treatment reduces the incidence of postoperative acute exacerbation of IPF in LC-IPF patients [239]. Moreover, experimental data have shown that the combination of pirfenidone and cisplatin may lead to an increase of CAF and tumour cell mortality in NSCLC preclinical models [240].

Advances in the understanding of IPF pathogenesis have resulted in further preclinical and clinical trials of drugs with antiproliferative and antifibrotic effects. For instance, tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, gefitinib, erlotinib, nintedanib, SU5918, and SU11657, are being investigated [241–247]. The important role of these inhibitors in cancer treatment was previously shown [248]. Indeed, gefitinib and erlotinib are important oral treatments for NSCLC patients with mutations that activate the epidermal growth factor receptor (EGFR). In IPF, imatinib was tested in fibrotic patients, but failed to show any benefit on survival or lung function [249]. In contrast, the VEGF, FGF, and PDGF receptor inhibitor, nintedanib, has been approved for IPF treatment. Additionally, this drug is also approved for use in combination with docetaxel as an effective second-line option for patients with advanced ADC-NSCLC who have been previously treated with one course of platinum-based therapy [250].

Another class of antifibrotic drugs are the mTOR kinase inhibitors, including everolimus, which failed as an IPF treatment [251]. However, everolimus has shown modest beneficial effects in patients with advanced NSCLC who were previously treated with chemotherapy alone, or with chemotherapy and EGFR inhibitors [252]. It is also approved as a second-line treatment in renal and breast cancer. Currently, there are efforts towards assessing the efficacy of a new mTOR kinase inhibitor (GSK-2126458) for IPF and advanced solid tumour treatment.

In addition to the previously mentioned therapeutic strategies, a broad range of IPF therapies are currently being tested in clinical trials (Table 5). Some of these therapies target molecules and mechanisms mentioned in this review, and which are hallmarks of the progression of both diseases. These include anti-IL-13 antibodies (QAX576 and Lebrikizumab), anti-CCL2 antibodies (Carlumab and CNTO-888), anti-TGFβ1 antibodies (Fresolimumab and GC1008), anti-integrin αvβ6 antibodies (BG0011 and STX-100), integrin αvβ6 antagonist drugs (GSK3008348), LPAR1 antagonist drugs (BMS-986020), ATX-inhibiting drugs (GLPG1690), angiostatic drugs (Tetrathiomolybdate), shh pathway-inhibiting drugs (vismodegib), and galectin-3-inhibiting drugs (TD139). Only two of these drugs are being clinically developed for NSCLC patients. Fresolimumab, which was tested in combination with stereotactic ablative radiotherapy in a phase I study, and tetrathiomolybdate in combination with carboplatin and pemetrexed, which is currently being tested in a phase I study. There are also preclinical studies for NSCLC that include some of these target molecules. For example, CCR2 antagonism was demonstrated to suppress CCL2-mediated viability, motility, and invasion of the NSCLC cell line, A549, in vitro [253]. Likewise, galectin-3 knockdown in NSCLC cell line-derived sphere resulted in attenuation of lung carcinogenesis by inhibiting stem-like properties [254]. In the same way, genetic deletion of ATX and LPAR1 was shown to attenuate lung carcinogenesis development in animal models [132]. Moreover, vismodegib is approved for the treatment of metastatic, local, or recurrent advanced basal cell carcinoma (BCC), although it has not been tested in NSCLC. Nevertheless, blockade of shh signaling synergistically has shown to increase sensitivity to EGFR-TKIs in primary and secondary resistant NSCLC cells [255].

Given the mechanistic similarities between LC and IPF diseases, and the concurrence of predominantly NSCLC and IPF, it is rational to consider the usefulness of the large number of approved NSCLC treatments for the management of pulmonary fibrosis. For example, Nivolumab is a new immunomodulatory agent that acts as a programmed death receptor-1-blocking antibody. One case study of an ADC patient with IPF showed a beneficial and sustained response in the lung, without any sign of IPF exacerbation after Nivolumab treatment [256]. This could be explained by the higher
expression of programmed cell death ligand 1 reported in cancer cells from UIP-associated SQC versus non-UIP SQC patients [257]. Other examples of feasible IPF and LC-IPF treatment candidates include vantictumab, which interferes with Wnt signalling and has undergone Phase I trials for NSCLC (preclinical studies of Wnt pathway inhibition have also been performed in pulmonary fibrosis [258,259]), and Muc1-based therapeutic strategies. Indeed, four Muc1-based Phase III trials exploring cancer treatment have been completed, one of which used a Muc1 tandem repeat peptide as an immunogen (L-BLP25) in patients with stage III unresectable NSCLC after chemoradiation [260].

Table 5. Development status of drugs targeting molecules and processes involved in lung cancer (LC) and Idiopathic pulmonary fibrosis (IPF).

| Therapy                              | IPF                                      | LC                                                      |
|--------------------------------------|------------------------------------------|---------------------------------------------------------|
| Anti-PDGFR, VEGFR, FGFR (nintedanib) | Approved                                 | Approved in combination with docetaxel (second-line treatment) for ADC-NSCLC |
| Anti-fibrotic drug (pirfenidone)     | Approved                                 | Preclinical studies for NSCLC [240]                     |
| Anti-IL13                            | QAX576 (NCT00532233, NCT01266135: Phase II completed), Lebrikizumab (NCT01872689: Phase II completed) | Not studied                                            |
| Anti-CCL2                            | Carlumab (CNTO-888) (NCT00786201: Phase II completed) | Preclinical studies for NSCLC [253]                     |
| Galectin-3 inhibition                | TD139 (NCT02257177: Phase I/II completed) | Preclinical studies for NSCLC [254]                     |
| Anti-TGFβ τ                          | Fresolimumab (GC1008) (NCT00125385: Phase I completed) | Fresolimumab (GC1008) (NCT02581787: Phase I/II suspended) (NSCLC patients) |
| Anti-αvβ6 integrin                    | BG0111 (STX-100) (NCT01371305: Phase II completed) | Not studied                                            |
| αvβ6 antagonist                       | GSK3008348 (NCT02612051: Phase I completed) | Not studied                                            |
| Anti-CTGF                             | Pamrevlumab (FG-3019) (NCT01262001: Phase II completed) | Not studied                                            |
| LPAR1 antagonist                      | BMS-986020 (NCT01766817: Phase II completed) | Preclinical studies [132]                              |
| Autotaxin inhibition                  | GLPG1690 (NCT02738801: Phase II completed) | Preclinical studies [132]                              |
| Angiostatic agent                     | Tetrathiomolybdate (NCT01089176: Phase I/II completed) | Tetrathiomolybdate (NCT01837329: Phase I recruiting patients) (NSCLC patients) |
| mTOR inhibitor                        | GSK-21264S (NCT01725139: Phase I completed) | Not studied *                                          |
|                                       | Sirolimus (NCT01462006: Not applicable Phase) |                                                          |
| TERT gene expression induction       | Nandrolone decanoate (NCT02055456: Phase I/II (unknown recruitment status)) | Not studied                                            |
| Shh pathway inhibitor                 | Vismodegib (NCT02648048: Phase Ib completed) | Preclinical studies for NSCLC [255]                     |
| Nivolumab                             | Not studied                              | Approved for NSCLC                                      |
| Notch pathway inhibitor               | Artesunate (preclinical studies [261])   | Rovalpituzumab (approved for SCLC)                       |
| Wnt pathway inhibitor                 | Preclinical studies [258,259]             | Vantictumab (NCT01957007: Phase I completed) (NSCLC patients) |
| Muc1-based therapies                  | Anti-KL-6 (preclinical studies [262])    | Muc1 immunogen (L-BLP25 (Phase III completed [260])) (NSCLC patients) |

IPF: idiopathic pulmonary fibrosis; LC: lung cancer; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; PDGFR: platelet derived growth factor receptor; VEGFR: vascular endothelial growth factor receptor; FGFR: fibroblast growth factor receptor; IL-13: interleukin 13; CCL2: chemokine ligand 2; TGFβ: transforming growth factor β; CTGF: connective tissue growth factor; LPAR1: lysophosphatidic acid receptor type 1; mTOR: mammalian Target of Rapamycin. * (NCT022581787: Phase I/II terminated for subjects with solid advanced tumors).
Finally, rovalpituzumab treatment, although not tested for NSCLC, is currently approved for SCLC, and it could also have potential in the treatment of IPF and LC-IPF, since it interferes with the Notch signalling pathway. In fact, it has been observed that artesunate ameliorates lung fibrosis via inhibiting the Notch signaling pathway in a rat bleomycin model [261].

7. Conclusions

The course of IPF disease and its resulting mortality are altered by the frequent co-occurrence of LC. This review supports the view of LC as a consequence of a genetic predisposition in IPF patients and, common cellular processes and molecular pathways between both diseases. Currently, there is no consensus regarding the treatment of patients with both diseases. However, pirfenidone and nintedanib are two novel drugs approved for IPF that have potential for treating patients with fibrosis, possibly extending the survival time and lowering the incidence of LC. However, we are some distance from realising effective therapeutic approaches that are capable of stopping the disease process, where disease progression still occurs in most IPF patients despite treatment. Nevertheless, we now have a great deal of knowledge about cancer biology and its similarities with IPF. Therefore, it seems reasonable to investigate whether specific cancer drugs may exert beneficial anti-fibrotic effects that are effective to treat LC-IPF patients. Furthermore, clinical trials that prospectively investigate the efficacy of currently approved anti-fibrotic agents (or agents under study) as treatments for LC-IPF patients are sorely needed.

Author Contributions: Conception and design: B.B., J.M. and J.C. Data acquisition: B.B., J.M., and J.C. Analysis and interpretation: B.B., J.M. and J.C. Writing and Original Draft Preparation, B.B., J.M. and J.C.; Writing Review & Editing, B.B., J.M. and J.C.; Visualization, B.B., J.M. and J.C.; Supervision, B.B., J.M. and J.C.; Project Administration, B.B., J.M. and J.C.; Funding Acquisition, B.B., J.M. and J.C.

Funding: This work was supported by the grants SAF2017–82913-R (J.C.), FIS PI17/02158 (J.M.), CIBERES (CB06/06/0027), TRACE (TRA2009–0311; Spanish Government), and by research grants from the Regional Government Prometeo 2017/023/UV (J.C.), ACIF/2016/341 (B.B.), from “Generalitat Valenciana”. Funding entities did not contribute to the study design or data collection, analysis and interpretation nor to the writing of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| IPF          | Idiopathic pulmonary fibrosis |
| UIP          | Usual interstitial pneumonia |
| LC           | Lung cancer |
| LC-IPF       | Lung cancer associated with idiopathic pulmonary fibrosis |
| NSCLC        | Non-small cell-lung cancer |
| ADC          | Adenocarcinoma |
| SQC          | Squamous cell carcinoma |
| SCLC         | Small cell lung cancer |
| ATII         | Alveolar type II cells |
| ECM          | Extracellular matrix |
| EMT          | Epithelial to mesenchymal transition |
| EndMT        | Endothelial to mesenchymal transition |
| α-SMA        | α-smooth muscle actin |
| CAF          | Cancer-associated fibroblast |
| ER           | Endoplasmic reticulum stress |
| TGFβ         | Transforming growth factor β |
| FGF          | Fibroblast growth factor |
| VEGF         | Vascular endothelial growth factor |
| PDGF         | Platelet derived growth factor |
| IL-13        | Interleukin-13 |
CCL2  Chemokine ligand 2  
CCR2  Chemokine receptor 2  
BALF  Bronchoalveolar lavage fluid  
LPA  Lysophosphatidic acid  
LPAR1  Lysophosphatidic acid receptor 1  
ATX  Autotaxin  
Shh  Sonic hedgehog  
TKI  Tyrosine kinase inhibitor  
EGFR  Epidermal growth factor  

References

1. Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.F.; Flaherty, K.R.; Lasky, J.A.; et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *Am. J. Respir. Crit. Care Med.* 2011, 183, 788–824. [CrossRef] [PubMed]

2. Ley, B.; Collard, H.R.; King, T.E., Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 2011, 183, 431–440. [CrossRef]

3. Meyer, E.C.; Liebow, A.A. Relationship of Interstitial Pneumonia Honeycombing and Atypical Epithelial Proliferation to Cancer of the Lung. *Cancer* 1965, 18, 322–351. [CrossRef]

4. Karampitsakos, T.; Tzilas, V.; Tringidou, R.; Steiropoulos, P.; Aidinis, V.; Papiris, S.A.; Bouros, D.; Tzouvelekis, A. Lung cancer in patients with idiopathic pulmonary fibrosis. *Pulm. Pharmacol. Ther.* 2017, 45, 1–10. [CrossRef] [PubMed]

5. Hubbard, R.; Venn, A.; Lewis, S.; Britton, J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. *Am. J. Respir. Crit. Care Med.* 2000, 161, 5–8. [CrossRef]

6. Wells, C.; Mannino, D.M. Pulmonary fibrosis and lung cancer in the United States: Analysis of the multiple cause of death mortality data, 1979 through 1991. *South. Med J.* 1996, 89, 505–510. [CrossRef] [PubMed]

7. Artinian, V.; Kvale, P.A. Cancer and interstitial lung disease. *Curr. Opin. Pulm. Med.* 2004, 10, 425–434. [CrossRef] [PubMed]

8. Kato, E.; Takayanagi, N.; Takaku, Y.; Kagiyama, N.; Kanauchi, T.; Ishiguro, T.; Sugita, Y. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. *ERJ Open Res.* 2018, 4, 00111-2016. [CrossRef]

9. Nagai, A.; Chiyotani, A.; Nakadate, T.; Konno, K. Lung cancer in patients with idiopathic pulmonary fibrosis. *Tohoku J. Exp. Med.* 1992, 167, 231–237. [CrossRef] [PubMed]

10. Aubry, M.C.; Myers, J.L.; Douglas, W.W.; Tazelaar, H.D.; Washington Stephens, T.L.; Hartman, T.E.; Deschamps, C.; Pankratz, V.S. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. *Mayo Clin. Proc.* 2002, 77, 763–770. [CrossRef]

11. Usui, K.; Tanai, C.; Tanaka, Y.; Noda, H.; Ishihara, T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. *Respirology* 2011, 16, 326–331. [CrossRef] [PubMed]

12. JafariNezhad, A.; YektaKooshali, M.H. Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *PLoS ONE* 2018, 13, e0202360. [CrossRef] [PubMed]

13. Matsushita, H.; Tanaka, S.; Saiki, Y.; Hara, M.; Nakata, K.; Tanimura, S.; Banba, J. Lung cancer associated with usual interstitial pneumonia. *Pathol. Int.* 1995, 45, 925–932. [CrossRef] [PubMed]

14. Park, J.; Kim, D.S.; Shim, T.S.; Lim, C.M.; Koh, Y.; Lee, S.D.; Kim, W.S.; Kim, W.D.; Lee, J.S.; Song, K.S. Lung cancer in patients with idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2001, 17, 1216–1219. [CrossRef] [PubMed]

15. Ozawa, Y.; Suda, T.; Naito, T.; Enomoto, N.; Hashimoto, D.; Fujisawa, T.; Nakamura, Y.; Inui, N.; Nakamura, H.; Chida, K. Cumulative incidence of and predictive factors for lung cancer in IPF. *Respirology* 2009, 14, 723–728. [CrossRef] [PubMed]

16. Lee, K.J.; Chung, M.P.; Kim, Y.W.; Lee, J.H.; Kim, K.S.; Ryu, J.S.; Lee, H.L.; Park, S.W.; Park, C.S.; Uh, S.T.; et al. Prevalence, risk factors and survival of lung cancer in the idiopathic pulmonary fibrosis. *Thorac. Cancer* 2012, 3, 150–155. [CrossRef] [PubMed]
37. Scotton, C.J.; Chambers, R.C. Molecular targets in pulmonary fibrosis: The myofibroblast in focus. *Chest* 2007, 132, 1311–1321. [CrossRef]
38. Singh, S.R.; Hall, I.P. Airway myofibroblasts and their relationship with airway myocytes and fibroblasts. *Proc. Am. Thorac. Soc.* 2008, 5, 127–132. [CrossRef]
39. Thannickal, V.J.; Toews, G.B.; White, E.S.; Lynch, J.P., 3rd; Martinez, F.J. Mechanisms of pulmonary fibrosis. *Annu. Rev. Med.* 2004, 55, 395–417. [CrossRef] [PubMed]
40. Evans, J.N.; Kelley, J.; Krill, J.; Low, R.B.; Adler, K.B. The myofibroblast in pulmonary fibrosis. *Chest* 1983, 83, 975–985. [CrossRef]
41. Kasai, H.; Allen, J.T.; Mason, R.M.; Kamimura, T.; Zhang, Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). *Respir. Res.* 2005, 6, 56. [CrossRef] [PubMed]
42. Yao, H.W.; Xie, Q.M.; Chen, J.Q.; Deng, Y.M.; Tang, H.F. TGF-beta1 induces alveolar epithelial to mesenchymal transition in vitro. *Life Sci.* 2004, 76, 29–37. [CrossRef] [PubMed]
43. Willis, B.C.; Liebler, J.M.; Luby-Phelps, K.; Nicholson, A.G.; Crandall, E.D.; du Bois, R.M.; Borok, Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: Potential role in idiopathic pulmonary fibrosis. *Am. J. Pathol.* 2005, 166, 1321–1332. [CrossRef]
44. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. *J. Clin. Investig.* 2009, 119, 1420–1428. [CrossRef] [PubMed]
45. Mehrad, B.; Strieter, R.M. Fibrocytes and the pathogenesis of diffuse parenchymal lung disease. *Fibrogenesis Tissue Repair* 2012, 5 (Suppl. 1), S22. [CrossRef]
46. Strieter, R.M. Pathogenesis and natural history of usual interstitial pneumonia: The whole story or the last chapter of a long novel. *Chest* 2005, 128, 5265–532S. [CrossRef] [PubMed]
47. Metz, C.N. Fibrocytes: A unique cell population implicated in wound healing. *Cell. Mol. Life Sci. CMLS* 2003, 60, 1342–1350. [CrossRef]
48. Phillips, R.J.; Burdick, M.D.; Hong, K.; Lutz, M.A.; Murray, L.A.; Xue, Y.Y.; Belperio, J.A.; Keane, M.P.; Strieter, R.M. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. *J. Clin. Investig.* 2004, 114, 438–446. [CrossRef]
49. Schmidt, M.; Sun, G.; Stacey, M.A.; Mori, L.; Mattoli, S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. *J. Immunol.* 2003, 171, 380–389. [CrossRef]
50. Almudever, P.; Milara, J.; De Diego, A.; Serrano-Mollar, A.; Xaubet, A.; Perez-Vizcaino, F.; Cogolludo, A.; Cortijo, J. Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis. *Thorax* 2013, 68, 938–948. [CrossRef]
51. Nataraj, D.; Ernst, A.; Kalluri, R. Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. *Am. J. Respir. Cell Mol. Biol.* 2010, 43, 129–130. [CrossRef] [PubMed]
52. Fernandez, I.E.; Eickelberg, O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. *Lancet* 2012, 380, 680–688. [CrossRef]
53. Hung, C.; Linn, G.; Chow, Y.H.; Kobayashi, A.; Mittelsteadt, K.; Altemeier, W.A.; Gharib, S.A.; Schnapp, L.M.; Duffield, J.S. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 2013, 188, 820–830. [CrossRef] [PubMed]
54. Zolak, J.S.; Jagirdar, R.; Surolia, R.; Karki, S.; Oliva, O.; Hock, T.; Guroji, P.; Ding, Q.; Liu, R.M.; Bolisetty, S.; et al. Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury. *Am. J. Pathol.* 2013, 182, 1239–1247. [CrossRef] [PubMed]
55. Nasreen, N.; Mohammed, K.A.; Mubarak, K.K.; Baz, M.A.; Akindipe, O.A.; Fernandez-Bussy, S.; Antony, V.B. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2009, 297, L115–L124. [CrossRef] [PubMed]
56. Mubarak, K.K.; Montes-Worboys, A.; Regev, D.; Nasreen, N.; Mohammed, K.A.; Faruqi, I.; Hensel, E.; Baz, M.A.; Akindipe, O.A.; Fernandez-Bussy, S.; et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2012, 39, 133–140. [CrossRef]
57. Horowitz, J.C.; Osterholzer, J.J.; Marazzi, A.; Stathopoulos, G.T. “Scar-cinoma”: Viewing the fibrotic lung mesenchymal cell in the context of cancer biology. *Eur. Respir. J.* 2016, 47, 1842–1854. [CrossRef] [PubMed]
58. Kalluri, R. The biology and function of fibroblasts in cancer. *Nat. Rev. Cancer* 2016, 16, 582–598. [CrossRef]
59. Königshoff, M. Lung cancer in pulmonary fibrosis: Tales of epithelial cell plasticity. *Respir. Int. Rev. Thorac. Dis.* 2011, 81, 353–358. [CrossRef]
60. Direkze, N.C.; Hodivala-Dilke, K.; Jeffery, R.; Hunt, T.; Poulsom, R.; Oukrif, D.; Alison, M.R.; Wright, N.A. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. *Cancer Res.* 2004, 64, 8492–8495. [CrossRef]  
61. Shiga, K.; Harra, M.; Nagasaki, T.; Sato, T.; Takahashi, H.; Takeyama, H. Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. *Cancers* 2015, 7, 2443–2458. [CrossRef] [PubMed]  
62. Zeisberg, E.M.; Potenta, S.; Xie, L.; Zeisberg, M.; Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. *Cancer Res.* 2007, 67, 10123–10128. [CrossRef]  
63. Hosaka, K.; Yang, Y.; Seki, T.; Fischer, C.; Dubey, O.; Fredlund, E.; Hartman, J.; Religa, P.; Morikawa, H.; Ishii, Y.; et al. Pericyte-fibroblast transition promotes tumor growth and metastasis. *Proc. Natl. Acad. Sci. USA* 2016, 113, E5618–E5627. [CrossRef] [PubMed]  
64. Rinkevich, Y.; Mori, T.; Sahoo, D.; Xu, P.X.; Bermingham, J.R., Jr.; Weissman, I.L. Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature. *Nat. Cell Biol.* 2012, 14, 1251–1260. [CrossRef] [PubMed]  
65. Tanjore, H.; Blackwell, T.S.; Lawson, W.E. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2012, 302, L721–L729. [CrossRef] [PubMed]  
66. Wolters, P.J.; Collard, H.R.; Jones, K.D. Pathogenesis of Idiopathic Pulmonary Fibrosis. *Annu. Rev. Pathol.* 2013. [CrossRef] [PubMed]  
67. Thannickal, V.J.; Horowitz, J.C. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. *Proc. Am. Thorac. Soc.* 2006, 3, 350–356. [CrossRef]  
68. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* 2011, 144, 646–674. [CrossRef]  
69. Tsai, Y.C.; Weissman, A.M. The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer. *Genes Cancer* 2010, 1, 764–778. [CrossRef]  
70. Lin, J.H.; Walter, P.; Yen, T.S. Endoplasmic reticulum stress in disease pathogenesis. *Annu. Rev. Pathol.* 2008, 3, 399–425. [CrossRef]  
71. Zhu, B.; Ferry, C.H.; Markell, L.K.; Blazanin, N.; Glick, A.B.; Gonzalez, F.J.; Peters, J.M. The nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) promotes oncogene-induced cellular senescence through repression of endoplasmic reticulum stress. *J. Biol. Chem.* 2014, 289, 20102–20119. [CrossRef] [PubMed]  
72. Araya, J.; Kojima, J.; Takasaka, N.; Itō, S.; Fujii, S.; Harra, H.; Yanagisawa, H.; Kobayashi, K.; Tsurushige, C.; Kawaishi, M.; et al. Insufficient autophagy in idiopathic pulmonary fibrosis. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2013, 304, L56–L69. [CrossRef] [PubMed]  
73. Patel, A.S.; Lin, L.; Geyer, A.; Kaspe, J.A.; An, C.H.; Cao, J.; Rosas, I.O.; Morse, D. Autophagy in idiopathic pulmonary fibrosis. *PLoS ONE* 2012, 7, e41394. [CrossRef] [PubMed]  
74. Sosulski, M.L.; Gongora, R.; Danchuk, S.; Doan, C.; Luo, F.; Sanchez, C.G. Deregulation of selective autophagy during aging and pulmonary fibrosis: The role of TGFbeta1. *Aging Cell* 2015, 14, 774–783. [CrossRef] [PubMed]  
75. Del Principe, D.; Vona, R.; Giordani, L.; Straface, E.; Giammarioli, A.M. Defective autophagy in fibroblasts may contribute to fibrogenesis in autoimmune processes. *Curr. Pharm. Des.* 2011, 17, 3878–3887. [CrossRef] [PubMed]  
76. Marino, G.; Niso-Santano, M.; Baehrecke, E.H.; Kroemer, G. Self-consumption: The interplay of autophagy and apoptosis. *Nat. Rev. Mol. Cell Biol.* 2014, 15, 81–94. [CrossRef] [PubMed]  
77. White, E. The role for autophagy in cancer. *J. Clin. Investig.* 2015, 125, 42–46. [CrossRef] [PubMed]  
78. Levy, J.M.M.; Towers, C.G.; Thorburn, A. Targeting autophagy in cancer. *Nat. Rev. Cancer* 2017, 17, 528–542. [CrossRef] [PubMed]  
79. Vancheri, C.; Sortino, M.A.; Tomaselli, V.; Mastrozzu, C.; Condorelli, F.; Bellistri, G.; Pistoreo, M.P.; Canonico, P.L.; Crimi, N. Different expression of TNF-alpha receptors and prostaglandin E(2)Production in normal and fibrotic lung fibroblasts: Potential implications for the evolution of the inflammatory process. *Am. J. Respir. Cell Mol. Biol.* 2002, 22, 628–634. [CrossRef] [PubMed]  
80. Moore, B.B.; Ballinger, M.N.; White, E.S.; Green, M.E.; Herrygens, A.B.; Wilke, C.A.; Toews, G.B.; Peters-Golden, M. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. *J. Immunol.* 2005, 174, 5644–5649. [CrossRef]
81. No, R.S.; Hergert, P.; Kahm, J.; Jessurun, J.; Henke, C. Pathological alteration of FoxO3a activity promotes idiopathic pulmonary fibrosis fibroblast proliferation on type I collagen matrix. *Am. J. Pathol.* 2011, 179, 2420–2430. [CrossRef] [PubMed]
82. Grimminger, F.; Gunther, A.; Vancheri, C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2015, 45, 1426–1433. [CrossRef] [PubMed]
83. Ramos, C.; Montano, M.; Garcia-Alvarez, J.; Ruiz, V.; Uhal, B.D.; Selman, M.; Pardo, A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. *Am. J. Respir. Cell Mol. Biol.* 2001, 24, 591–598. [CrossRef] [PubMed]
84. Mio, T.; Nagai, S.; Kitaichi, M.; Kawatani, A.; Izumi, T. Proliferative characteristics of fibroblast lines derived from open lung biopsy specimens of patients with IPF (UIP). *Chest* 1992, 102, 832–837. [CrossRef] [PubMed]
85. Raghu, G.; Chen, Y.Y.; Rusch, V.; Rabinovitch, P.S. Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. *Am. Rev. Respir. Dis.* 1988, 138, 703–708. [CrossRef] [PubMed]
86. Losa, D.; Chanson, M.; Crespin, S. Connexins as therapeutic targets in lung disease. *Expert Opin. Ther. Targets* 2011, 15, 989–1002. [CrossRef] [PubMed]
87. Trovato-Salinaro, A.; Trovato-Salinaro, E.; Failla, M.; Mastruzello, C.; Tomaselli, V.; Gili, E.; Crimi, N.; Condorelli, D.F.; Vancheri, C. Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis. *Respir. Res.* 2006, 7, 122. [CrossRef]
88. Cesen-Cummings, K.; Fernstrom, M.J.; Malkinson, A.M.; Ruch, R.J. Frequent reduction of gap junctional intercellular communication and connexin43 expression in human and mouse lung carcinoma cells. *Carcinogenesis* 1998, 19, 61–67. [CrossRef]
89. Schafer, M.J.; White, T.A.; Iijima, K.; Haak, A.J.; Ligresti, G.; Atkinson, E.J.; Oberg, A.L.; Birch, J.; Salmonowicz, H.; Zhu, Y.; et al. Cellular senescence mediates fibrotic pulmonary disease. *Nat. Commun.* 2017, 8, 14532. [CrossRef]
90. Dimri, G.P. What has senescence got to do with cancer? *Cancer Cell* 2005, 7, 505–512. [CrossRef] [PubMed]
91. Krtolica, A.; Parrinello, S.; Lockett, S.; Desprez, P.Y.; Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. *Proc. Natl. Acad. Sci. USA* 2001, 98, 12072–12077. [CrossRef] [PubMed]
92. Arenberg, D.A. Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: A role for phosphatase and tensin homologue deleted on chromosome 10. *Am. J. Respir. Crit. Care Med.* 2003, 168, 436–442. [CrossRef] [PubMed]
93. Lefkowitz, R.J.; et al. beta-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. *Sci. Transl. Med.* 2011, 3, 74ra23. [CrossRef]
94. Vancheri, C. Common pathways in idiopathic pulmonary fibrosis and cancer. *Eur. Respir. Rev. Off. J. Eur. Respir. Soc.* 2013, 22, 265–272. [CrossRef] [PubMed]
95. Moriya, Y.; Iwai, T.; Yamada, T.; Matsuno, Y.; Kondo, H.; Hirohashi, S. Increased expression of laminin-5 and its prognostic significance in lung adenocarcinomas of small size. An immunohistochemical analysis of 102 cases. *Cancer* 2001, 91, 1129–1141. [CrossRef]
96. Carrido, C.; Schmitt, E.; Cande, C.; Vahsen, N.; Parcellier, A.; Kroemer, G. HSP27 and HSP70: Potentially oncogenic apoptosis inhibitors. *Cell Cycle* 2003, 2, 579–584. [CrossRef]
97. Pelosi, G.; Pastorino, U.; Pasini, F.; Maisonneuve, P.; Fraggetta, F.; Iannucci, A.; Sonzogni, A.; De Manzoni, G.; Terzi, A.; Durante, E.; et al. Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. *Br. J. Cancer* 2003, 88, 537–547. [CrossRef]
98. Chilosi, M.; Zamo, A.; Doglioni, C.; Reghellin, D.; Lestani, M.; Montagna, L.; Pedron, S.; Ennas, M.G.; Cancellieri, A.; Murer, B.; et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. *Respir. Res.* 2006, 7, 95. [CrossRef]
99. Zhang, L.; Wang, Y.; Wu, G.; Xiong, W.; Gu, W.; Wang, C.Y. Macrophages: Friend or foe in idiopathic pulmonary fibrosis? *Respir. Res.* 2018, 19, 170. [CrossRef]
101. Barron, L.; Wynn, T.A. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2011**, *300*, G723–G728. [CrossRef] [PubMed]

102. Ballinger, M.N.; Newstead, M.W.; Zeng, X.; Bhan, U.; Mo, X.M.; Kunkel, S.L.; Moore, B.B.; Flavell, R.; Christman, J.W.; Standiford, T.J. IRAK-M promotes alternative macrophage activation and fibroproliferation in bleomycin-induced lung injury. *J. Immunol.* **2015**, *194*, 1894–1904. [CrossRef] [PubMed]

103. Osterholzer, J.J.; Olszewski, M.A.; Murdock, B.J.; Chen, G.H.; Erb-Downward, J.R.; Subbotina, N.; Browning, K.; Lin, Y.; Morey, R.E.; Dayrit, J.K.; et al. Implicating exudate macrophages and Ly-6C(high) monocytes in CCR2-dependent lung fibrosis following gene-targeted alveolar injury. *J. Immunol.* **2013**, *190*, 3447–3457. [CrossRef]

104. Craig, V.J.; Zhang, L.; Hagood, J.S.; Owen, C.A. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. *Am. J. Respir. Cell Mol. Biol.* **2015**, *53*, 585–600. [CrossRef] [PubMed]

105. Murray, P.J.; Wynn, T.A. Protective and pathogenic functions of macrophage subsets. *Nat. Rev. Immunol.* **2011**, *11*, 723–737. [CrossRef] [PubMed]

106. Noy, R.; Pollard, J.W. Tumor-associated macrophages: From mechanisms to therapy. *Immunity* **2014**, *41*, 49–61. [CrossRef] [PubMed]

107. Akhurst, R.J.; Hata, A. Targeting the TGFbeta signalling pathway in disease. *Nat. Rev. Drug Discov.* **2012**, *11*, 790–811. [CrossRef] [PubMed]

108. Kelly, M.; Kolb, M.; Bonniaud, P.; Gauldie, J. Re-evaluation of fibrogenic cytokines in lung fibrosis. *Curr. Pharm. Des.* **2003**, *9*, 39–49. [CrossRef]

109. O’Riordan, T.G.; Smith, V.; Raghu, G. Development of novel agents for idiopathic pulmonary fibrosis: Progress in target selection and clinical trial design. *Chest* **2015**, *148*, 1083–1092. [CrossRef]

110. Roberts, A.B.; Wakefield, L.M. The two faces of transforming growth factor beta in carcinogenesis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2011**, *300*, G723–G728. [CrossRef] [PubMed]

111. Hetzel, M.; Bachem, M.; Anders, D.; Trischler, G.; Faehling, M. Different effects of growth factors on proliferation of pulmonary interstitial fibroblasts is... [CrossRef] [PubMed]

112. Bonner, J.C. Regulation of PDGF and its receptors in fibrotic diseases. *Cytokine Growth Fact. Rev.* **2004**, *15*, 255–273. [CrossRef] [PubMed]

113. Noskovicova, N.; Petrek, M.; Eickelberg, O.; Heinzelmann, K. Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies. *Am. J. Respir. Cell Mol. Biol.* **2015**, *52*, 263–284. [CrossRef] [PubMed]

114. Battegay, E.J.; Raines, E.W.; Seifert, R.A.; Bowen-Pope, D.F.; Ross, R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. *Cell* **1990**, *63*, 515–524. [CrossRef]

115. Battegay, E.J.; Raines, E.W.; Colbert, T.; Ross, R. TNF-alpha stimulation of fibroblast proliferation. *Am. J. Physiol. Gastrointest. Liver Physiol.* **1999**, *75*, 6040–6047. [CrossRef] [PubMed]

116. Wang, P.; Song, L.; Ge, H.; Jin, P.; Jiang, Y.; Hu, W.; Geng, N. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. *Oncotargets Ther.* **2014**, *7*, 1761–1768. [CrossRef]

117. Shikada, Y.; Yonemitsu, Y.; Koga, T.; Onimaru, M.; Nakano, T.; Okano, S.; Sata, S.; Nakagawa, K.; Yoshino, I.; Machara, Y.; et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. *Cancer Res.* **2005**, *65*, 7241–7248. [CrossRef]

118. Chaudhary, N.I.; Roth, G.J.; Hilberg, F.; Muller-Quernheim, J.; Prasse, A.; Zissel, G.; Schnapp, A.; Park, J.E. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. *Eur. Respir. J.* **2007**, *29*, 976–985. [CrossRef]

119. Frezzetti, D.; Gallo, M.; Maiello, M.R.; D’Alessio, A.; Esposito, C.; Chichinelli, N.; Normanno, N.; De Luca, A. VEGF as a potential target in lung cancer. *Expert Opin. Ther. Targets* **2017**, *21*, 959–966. [CrossRef]

120. Zhang, S.; Smartt, H.; Holgate, S.T.; Roche, W.R. Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: An in vitro co-culture model of airway remodeling in asthma. *Lab. Investig. A J. Tech. Methods Pathol.* **1999**, *79*, 395–405.

121. Khalil, N.; Xu, Y.D.; O’Connor, R.; Duronio, V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. *J. Biol. Chem.* **2005**, *280*, 43000–43009. [CrossRef] [PubMed]
122. Guzy, R.D.; Li, L.; Smith, C.; Dorry, S.J.; Koo, H.Y.; Chen, L.; Ornitz, D.M. Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling. *J. Biol. Chem.* 2017, 292, 10364–10378. [CrossRef] [PubMed]

123. Suzuki, T.; Yasuda, H.; Funaiishi, K.; Arai, D.; Ishioka, K.; Ogino, K.; Tani, T.; Hamamoto, J.; Ohashi, A.; Naoki, K.; et al. Multiple roles of extracellular fibroblast growth factors in lung cancer cells. *Int. J. Oncol.* 2015, 46, 423–429. [CrossRef] [PubMed]

124. Allen, J.T.; Knight, R.A.; Bloor, C.A.; Spiteri, M.A. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. *Am. J. Respir. Cell Mol. Biol.* 1999, 21, 693–700. [CrossRef] [PubMed]

125. Chang, C.C.; Shih, J.Y.; Jeng, Y.M.; Su, J.L.; Lin, B.Z.; Chen, S.T.; Chau, Y.P.; Yang, P.C.; Kuo, M.L. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. *J. Natl. Cancer Inst.* 2004, 96, 364–375. [CrossRef] [PubMed]

126. Chien, W.; Yin, D.; Gui, D.; Mori, A.; Frank, J.M.; Said, J.; Kusuanco, D.; Marchevsky, A.; McKenna, R.; Koeffler, H.P. Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. *Mol. Cancer Res. MCR* 2006, 4, 591–598. [CrossRef] [PubMed]

127. Allen, J.T.; Spiteri, M.A. Growth factors in idiopathic pulmonary fibrosis: Relative roles. *Respir. Res.* 2002, 3, 13. [CrossRef]

128. Kelly, K.; Kane, M.A.; Bunn, P.A., Jr. Growth factors in lung cancer: Possible etiologic role and clinical target. *Med. Pediatr. Oncol.* 1991, 19, 450–458. [CrossRef] [PubMed]

129. Hodkinson, P.S.; Mackinnon, A.; Sethi, T. Targeting growth factors in lung cancer. *Chest* 2008, 133, 1209–1216. [CrossRef] [PubMed]

130. Funke, M.; Zhao, Z.; Xu, Y.; Chun, J.; Tager, A.M. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. *Am. J. Respir. Cell Mol. Biol.* 2012, 46, 355–364. [CrossRef]

131. Tager, A.M.; LaCamera, P.; Shea, B.S.; Campanella, G.S.; Selman, M.; Zhao, Z.; Polosukhin, V.; Wain, J.; Karimi-Shah, B.A.; Kim, N.D.; et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. *Nat. Med.* 2008, 14, 45–54. [CrossRef] [PubMed]

132. Magkrioti, C.; Oikonomou, N.; Kaffe, E.; Mouratis, M.A.; Xylourgidis, N.; Barbayianni, I.; Megadoukas, P.; Harokopos, V.; Valavanis, C.; Chun, J.; et al. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis. *Cancer Res.* 2018, 78, 3634–3644. [CrossRef] [PubMed]

133. Zhu, Z.; Homer, R.J.; Wang, Z.; Chen, Q.; Geba, G.P.; Wang, J.; Zhang, Y.; Elias, J.A. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and ectasin production. *J. Clin. Investig.* 1999, 103, 773–788. [CrossRef]

134. Hancock, A.; Armstrong, L.; Gama, R.; Millar, A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. *Am. J. Respir. Cell Mol. Biol.* 1998, 18, 60–65. [CrossRef] [PubMed]

135. Ingram, J.L.; Rice, A.B.; Geisenhoffer, K.; Madtes, D.K.; Bonner, J.C. IL-13 and IL-1beta promote lung fibroblast growth through coordinated up-regulation of PDGF-AA and PDGF-Ralpha. *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* 2004, 18, 1132–1134.

136. Kaviratne, M.; Hesse, M.; Leusink, M.; Cheever, A.W.; Davies, S.J.; McKerrow, J.H.; Wakefield, L.M.; Letterio, J.J.; Wynn, T.A. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. *J. Immunol.* 2004, 173, 4020–4029. [CrossRef]

137. Lee, C.G.; Kang, H.R.; Homer, R.J.; Chupp, G.; Elias, J.A. Transgenic modeling of transforming growth factor-beta(1): Role of apoptosis in fibrosis and alveolar remodeling. *Proc. Am. Thorac. Soc.* 2006, 3, 418–423. [CrossRef]

138. Huang, M.; Wang, J.; Lee, P.; Sharma, S.; Mao, J.T.; Meissner, H.; Uyemura, K.; Modlin, R.; Wollman, J.; Dubinett, S.M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. *Cancer Res.* 1995, 55, 3847–3853.

139. Pastuszak-Lewandoska, D.; Domanska-Senderowska, D.; Antczak, A.; Kordiak, J.; Gorski, P.; Czarnecka, K.H.; Migdalska-Sek, M.; Nawrot, E.; Kiszalkiewicz, J.M.; Brzezianska-Lasota, E. The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma. *Mol. Diagn. Ther.* 2018, 22, 621–629. [CrossRef] [PubMed]
140. Xie, M.; Wu, X.J.; Zhang, J.J.; He, C.S. IL-13 receptor alpha2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice. *OncoTarget* 2015, 6, 32902–32913. [CrossRef]

141. Chakraborty, S.; Chopra, P.; Ambi, S.V.; Dastidar, S.G.; Ray, A. Emerging therapeutic interventions for idiopathic pulmonary fibrosis. *Expert Opin. Investig. Drugs* 2014, 23, 893–910. [CrossRef] [PubMed]

142. Gu, L.; Tseng, S.; Horner, R.M.; Tam, C.; Loda, M.; Rollins, B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. *Nature* 2000, 404, 407–411. [CrossRef] [PubMed]

143. Zhang, X.W.; Qin, X.; Qin, C.Y.; Yin, Y.L.; Chen, Y.; Zhu, H.L. Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance. *Cancer Immunol. Immunother.* 2013, 62, 563–570. [CrossRef] [PubMed]

144. Vancheri, C.; Failla, M.; Crimi, N.; Raghu, G. Idiopathic pulmonary fibrosis: A disease with similarities and links to cancer biology. *Eur. Respir. J.* 2010, 35, 496–504. [CrossRef] [PubMed]

145. Zhang, C.; Lan, T.; Hou, J.; Li, J.; Fang, R.; Yang, Z.; Zhang, M.; Liu, J.; Liu, B. NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling. *OncoTarget* 2014, 5, 4392–4405. [CrossRef] [PubMed]

146. Swamy, S.M.; Rajasekaran, N.S.; Thannickal, V.J. Nuclear Factor-Erythroid-2-Related Factor 2 in Aging and Lung Fibrosis. *Am. J. Pathol.* 2016, 186, 1712–1723. [CrossRef] [PubMed]

147. Tong, Y.H.; Zhang, B.; Fan, Y.; Lin, N.M. Keap1-Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics. *Chronic Dis. Transl. Med.* 2015, 1, 175–186. [CrossRef]

148. Seibold, M.A.; Wise, A.L.; Speer, M.C.; Steele, M.P.; Brown, K.K.; Loyd, J.E.; Fingerlin, T.E.; Zhang, W.; Gudmundsson, G.; Groshong, S.D.; et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. *N. Engl. J. Med.* 2011, 364, 1503–1512. [CrossRef]

149. Yu, C.J.; Yang, P.C.; Shun, C.T.; Lee, Y.C.; Kuo, S.H.; Luh, K.T. Overexpression of MUC5 genes is associated with early post-operative metastasis in non-small-cell lung cancer. *Int. J. Cancer* 1996, 69, 457–465. [CrossRef]

150. Nagashio, R.; Ueda, J.; Ryuge, S.; Nakashima, H.; Jiang, S.X.; Kobayashi, M.; Yanagita, K.; Katono, K.; Satoh, Y.; Masuda, N.; et al. Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer. *Sci. Rep.* 2015, 5, 8649. [CrossRef]

151. Ballester, B.; Milara, J.; Sanz, C.; González, S.; Guijarro, R.; Martínez, C.; Cortijo, J. Role of MUC1 in idiopathic pulmonary fibrosis. In Proceedings of the European Respiratory Society Congress, London, UK, 3–7 September 2016.

152. Ballester, B.; Milara, J.; Guijarro, R.; Morcillo, E.; Cortijo, J. Role of MUC4 in idiopathic pulmonary fibrosis. In Proceedings of the European Respiratory Society Congress, Paris, France, 15–19 September 2018.

153. Ballester, B.; Roger, I.; Contreras, S.; Montero, P.; Milara, J. Role of MUC1 in idiopathic pulmonary fibrosis: Mechanistic insights. In Proceedings of the European Respiratory Society Congress, Milan, Italy, 9–13 September 2017.

154. Ishikawa, N.; Hattori, N.; Yokoyama, A.; Kohno, N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. *Respir. Investig.* 2012, 50, 3–13. [CrossRef]

155. Bafna, S.; Kaur, S.; Batra, S.K. Membrane-bound mucins: The mechanistic basis for alterations in the growth and survival of cancer cells. *Oncoogene* 2010, 29, 2893–2904. [CrossRef]

156. Stroopinsky, D.; Rajabi, H.; Nahas, M.; Rosenblatt, J.; Rahimian, M.; Pyzer, A.; Tagde, A.; Kharbanda, A.; Jain, S.; Kufe, T.; et al. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. *J. Cell. Mol. Med.* 2018. [CrossRef] [PubMed]

157. Taylor-Papadimitriou, J.; Burchell, J.M.; Graham, R.; Beatson, R. Latest developments in MUC1 immunotherapy. *Biochem. Soc. Trans.* 2018, 46, 659–668. [CrossRef] [PubMed]

158. Lederer, D.J.; Martinez, F.J. Idiopathic Pulmonary Fibrosis. *N. Engl. J. Med.* 2018, 378, 1811–1823. [CrossRef] [PubMed]

159. Mackinnon, A.C.; Gibbons, M.A.; Farnworth, S.L.; Leffler, H.; Nilsson, U.J.; Delaine, T.; Simpson, A.J.; Forbes, S.J.; Hirani, N.; Gauldie, J.; et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. *Am. J. Respir. Crit. Care Med.* 2012, 185, 537–546. [CrossRef]

160. Ramasamy, S.; Duraisamy, S.; Barbashov, S.; Kawano, T.; Kharbanda, S.; Kufe, D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. *Mol. Cell* 2007, 27, 992–1004. [CrossRef] [PubMed]
161. Farhad, M.; Rolig, A.S.; Redmond, W.L. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. *Oncology* 2018, 7, e1434467. [CrossRef]

162. Selman, M.; Pardo, A.; Kaminski, N. Idiopathic pulmonary fibrosis: Aberrant recapitulation of developmental programs? *PLoS Med.* 2008, 5, e62. [CrossRef]

163. Chilosi, M.; Poletti, V.; Zamo, A.; Lestani, M.; Montagna, L.; Piccoli, P.; Pedron, S.; Bertaso, M.; Scarpa, A.; Murer, B.; et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. *Am. J. Pathol.* 2003, 162, 1495-1502. [CrossRef]

164. Stewart, D.J. Wnt signaling pathway in non-small cell lung cancer. *J. Natl. Cancer Inst.* 2014, 106, djt356. [CrossRef]

165. Coon, D.R.; Roberts, D.J.; Loscertales, M.; Kradin, R. Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia. *Exp. Mol. Pathol.* 2006, 80, 119–123. [CrossRef] [PubMed]

166. Stewart, G.A.; Hoyne, G.F.; Ahmad, S.A.; Jarman, E.; Wallace, W.A.; Harrison, D.J.; Haslett, C.; Lamb, J.R.; Howie, S.E. Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. *J. Pathol.* 2003, 199, 488–495. [CrossRef]

167. Moshai, E.F.; Wemeau-Stervinou, L.; Cigna, N.; Brayer, S.; Somme, J.M.; Crestani, B.; Mailleux, A.A. Targeting the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice. *Am. J. Respir. Cell Mol. Biol.* 2014, 51, 11–25. [CrossRef] [PubMed]

168. Giroux-Leprieur, E.; Costantini, A.; Ding, V.W.; He, B. Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance. *Int. J. Mol. Sci.* 2018, 19, 2835. [CrossRef] [PubMed]

169. Ye, Y.Z.; Zhang, Z.H.; Fan, X.Y.; Xu, X.L.; Chen, M.L.; Chang, M.W.; Zhang, Y.B. Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer. *Med. Oncol.* 2013, 30, 595. [CrossRef]

170. Westhoff, B.; Colaluca, I.N.; D’Ario, G.; Donzelli, M.; Tosoni, D.; Volorio, S.; Pelosi, G.; Spaggiari, L.; Mazzarol, G.; Viale, G.; et al. Alterations of the Notch pathway in lung cancer. *Proc. Natl. Acad. Sci. USA* 2009, 106, 22229–22298. [CrossRef]

171. Zou, B.; Zhou, X.L.; Lai, S.Q.; Liu, J.C. Notch signaling and non-small cell lung cancer. *Oncol. Lett.* 2018, 51, 1–7. [CrossRef] [PubMed]

172. Lawrence, J.; Nho, R. The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis. *Am. J. Respir. Cell Mol. Biol.* 1992, 51, 1–7. [CrossRef] [PubMed]

173. Conte, E.; Fruciano, M.; korfei, M.; Fagone, E.; Iemmolo, M.; Lo Furno, D.; Giuffrida, R.; Crimi, N.; Guenther, A.; et al. PI3K p110gamma overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: In vitro effects of its inhibition. *Lab. Invest.* 2013, 93, 566–576. [CrossRef]

174. Horowitz, J.C.; Lee, D.Y.; Waghray, M.; Keshamouni, V.G.; Thomas, P.E.; Zhang, H.; Cui, Z.; Thannickal, V.J. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. *J. Biol. Chem.* 2004, 279, 1359–1367. [CrossRef] [PubMed]

175. Kavanaugh, W.M.; Klippel, A.; Escobedo, J.A.; Williams, L.T. Modification of the 85-kilodalton subunit of the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice. *PLoS ONE* 2011, 6, e24663. [CrossRef] [PubMed]

176. Fumarola, C.; Bonelli, M.A.; Petronini, P.G.; Alifieri, R.R. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. *Biochem. Pharmacol.* 2014, 90, 197–207. [CrossRef] [PubMed]

177. Mulugeta, S.; Nguyen, V.; Russo, S.J.; Muniswamy, M.; Beers, M.F. A surfactant protein C precursor protein associates with altered surfactant protein processing and herpesvirus infection. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2008, 294, L1119–L1126. [CrossRef]
180. Van Moorsel, C.H.; Ten Klooster, L.; van Oosterhout, M.F.; de Jong, P.A.; Adams, H.; Wouter van Es, H.; Ruven, H.J.; van der Vis, J.J.; Grutters, J.C. SFTP A2 Mutations in Familial and Sporadic Idiopathic Interstitial Pneumonia. *Am. J. Respir. Crit. Care Med.* 2015, 192, 1249–1252. [CrossRef] [PubMed]

181. Armarios, M.Y.; Chen, J.J.; Cogan, J.D.; Alder, J.K.; Ingersoll, R.G.; Markin, C.; Lawson, W.E.; Xie, M.; Vulto, I.; Phillips, J.A., 3rd; et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. *N. Engl. J. Med.* 2007, 356, 1317–1326. [CrossRef] [PubMed]

182. Takeda, T.; Munakata, M.; Ohtsuka, Y.; Nisihara, H.; Nasuhara, Y.; Kamachi-Satoh, A.; Dosaka-Akita, H.; Noth, I.; Zhang, Y.; Ma, S.F.; Flores, C.; Barber, M.; Huang, Y.; Broderick, S.M.; Wade, M.S.; Hysi, P.; Petrovski, S.; Todd, J.L.; Durheim, M.T.; Wang, Q.; Chien, J.W.; Kelly, F.L.; Frankel, C.; Mebane, C.M.; Ren, Z.; Fingerlin, T.E.; Murphy, E.; Zhang, W.; Peljto, A.L.; Brown, K.K.; Steele, M.P.; Loyd, J.E.; Cosgrove, G.P.; Stuart, B.D.; Choi, J.; Zaidi, S.; Xing, C.; Holohan, B.; Chen, R.; Choi, M.; Dharwardkar, P.; Torres, F.; Girod, C.E.; et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. *Nat. Genet.* 2015, 47, 512–517. [CrossRef]

183. Karachaliou, N.; Mayo, C.; Costa, C.; Magri, I.; Gimenez-Capitan, A.; Molina-Vila, M.A.; Rosell, R. KRAS mutations in lung cancer. *Clin. Lung Cancer* 2013, 14, 205–214. [CrossRef]

184. Masai, K.; Tsuta, K.; Motoi, N.; Shiraiishi, K.; Furuta, K.; Suzuki, S.; Asakura, K.; Nakagawa, K.; Sakurai, H.; Watanabe, S.I.; et al. Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern. *J. Thorac. Oncol. Off. Publ. Int. Assoc. Stud. Lung Cancer* 2016, 11, 2141–2149. [CrossRef] [PubMed]

185. Armanios, M.Y.; Chen, J.J.; Cogan, J.D.; Alder, J.K.; Ingersoll, R.G.; Markin, C.; Lawson, W.E.; Xie, M.; Vulto, I.; Phillips, J.A., 3rd; et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. *N. Engl. J. Med.* 2007, 356, 1317–1326. [CrossRef] [PubMed]

186. Sozzi, G.; Miozzo, M.; Donghi, R.; Pilotti, S.; Cariani, C.T.; Pastorino, U.; Della Porta, G.; Pierotti, M.A. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. *Cancer Res.* 1996, 53, 4817–4822. [PubMed]

187. Bennett, W.P.; Colby, T.V.; Travis, W.D.; Borkowski, A.; Jones, R.T.; Lane, D.P.; Metcalf, R.A.; Samet, J.M.; Takeshima, Y.; Gu, J.R.; et al. p53 protein accumulates frequently in early bronchial neoplasia. *Takeshima, Y.; Gu, J.R.; et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res.* 1996, 53, 4817–4822. [PubMed]

188. Armanios, M.Y.; Chen, J.J.; Cogan, J.D.; Alder, J.K.; Ingersoll, R.G.; Markin, C.; Lawson, W.E.; Xie, M.; Vulto, I.; Phillips, J.A., 3rd; et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. *N. Engl. J. Med.* 2007, 356, 1317–1326. [CrossRef] [PubMed]

189. Bennett, W.P.; Colby, T.V.; Travis, W.D.; Borkowski, A.; Jones, R.T.; Lane, D.P.; Metcalf, R.A.; Samet, J.M.; Takeshima, Y.; Gu, J.R.; et al. p53 protein accumulates frequently in early bronchial neoplasia. *Cancer Res.* 1996, 53, 4817–4822. [PubMed]
198. Wang, Y.; Kuan, P.J.; Xing, C.; Cronkhite, J.T.; Torres, F.; Rosenblatt, R.L.; DiMaio, J.M.; Kinch, L.N.; Grishin, N.V.; Garcia, C.K. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. *Am. J. Hum. Genet.* 2009, 84, 52–59. [CrossRef] [PubMed]

199. Nathan, N.; Giraud, V.; Picard, C.; Nunes, H.; Dastot-Le Moal, F.; Copin, B.; Galeron, L.; De Ligniville, A.; Kuziner, N.; Reynaud-Gaubert, M.; et al. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. *Hum. Mol. Genet.* 2016, 25, 1457–1467. [CrossRef] [PubMed]

200. Maitra, M.; Wang, Y.; Gerard, R.D.; Mendelson, C.R.; Garcia, C.K. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. *J. Biol. Chem.* 2010, 285, 22103–22113. [CrossRef]

201. Madsen, J.; Tornoe, I.; Nielsen, O.; Koch, C.; Steinhilber, W.; Holmskov, U. Expression and localization of lung surfactant protein A in human tissues. *Am. J. Respir. Cell Mol. Biol.* 2003, 29, 591–597. [CrossRef]

202. Chen, Z.; Fillmore, C.M.; Hammerman, P.S.; Kim, C.F.; Wong, K.K. Non-small-cell lung cancers: A heterogeneous set of diseases. *Nat. Rev. Cancer* 2014, 14, 535–546. [CrossRef]

203. Kropski, J.A.; Blackwell, T.S.; Loyd, J.E. The genetic basis of idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2015, 45, 1717–1727. [CrossRef]

204. Korthagen, N.M.; van Moorsel, C.H.; Barlo, N.P.; Kazemier, K.M.; Ruven, H.J.; Grutters, J.C. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. *PLoS ONE* 2012, 7, e30442. [CrossRef] [PubMed]

205. Landi, M.T.; Chatterjee, N.; Yu, K.; Goldin, L.R.; Goldstein, A.M.; Rotunno, M.; Mirabello, L.; Jacobs, K.; Wheeler, W.; Yeager, M.; et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. *Am. J. Hum. Genet.* 2009, 85, 679–691. [CrossRef] [PubMed]

206. Ye, G.; Tan, N.; Meng, C.; Li, J.; Jing, L.; Yan, M.; Jin, T.; Chen, F. Genetic variations in TERC and TERT genes are associated with lung cancer risk in a Chinese Han population. *Oncotarget* 2017, 8, 110145–110152. [CrossRef] [PubMed]

207. McKay, J.D.; Hung, R.J.; Han, Y.; Zong, X.; Carreras-Torres, R.; Christiani, D.C.; Caporaso, N.E.; Johannson, M.; Xiao, X.; Li, Y.; et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat. Genet.* 2017, 49, 1126–1132. [CrossRef] [PubMed]

208. Kang, J.U.; Koo, S.H.; Kwon, K.C.; Park, J.W.; Kim, J.M. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. *Cancer Genet. Cytogenet.* 2008, 182, 1–11. [CrossRef] [PubMed]

209. Wu, X.; Amos, C.I.; Zhu, Y.; Zhao, H.; Grossman, B.H.; Shay, J.W.; Spitz, M.R. Telomere dysfunction: A potential cancer predisposition factor. *J. Natl. Cancer Inst.* 2003, 95, 1211–1218. [CrossRef] [PubMed]

210. Hackett, J.A.; Feldser, D.M.; Greider, C.W. Telomere dysfunction increases mutation rate and genomic instability. *Cell* 2001, 106, 275–286. [CrossRef]

211. Mora, A.L.; Rojas, M.; Pardo, A.; Selman, M. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. *Nat. Rev. Drug Discov.* 2017, 16, 810. [CrossRef]

212. Peljto, A.L.; Zhang, Y.; Fingerlin, T.E.; Ma, S.F.; Garcia, J.G.; Richards, T.J.; Silveira, L.J.; Lindell, K.O.; Steele, M.P.; Loyd, J.E.; et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *JAMA* 2013, 309, 2232–2239. [CrossRef]

213. Yang, J.; Xu, T.; Gomez, D.R.; Jeter, M.; Levy, L.B.; Song, Y.; Hahn, S.; Liao, Z.; Yuan, X. The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy. *Transl. Oncol.* 2017, 10, 197–202. [CrossRef]

214. Rabinovich, E.I.; Kapetanaki, M.G.; Steinfield, I.; Gibson, K.F.; Pandit, K.V.; Yu, G.; Yakhini, Z.; Kaminski, N. Global methylation patterns in idiopathic pulmonary fibrosis. *PLoS ONE* 2012, 7, e33770. [CrossRef] [PubMed]

215. Takenaka, K.; Gemma, A.; Yoshimura, A.; Hosoya, Y.; Nara, M.; Hosomi, Y.; Okano, T.; Kunugi, S.; Kozumi, K.; Fukuda, Y.; et al. Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis. *Mol. Med. Rep.* 2009, 2, 73–80. [PubMed]
216. Schutte, M.; Hruban, R.H.; Hedrick, L.; Cho, K.R.; Nadasdy, G.M.; Weinstein, C.L.; Bova, G.S.; Isaacs, W.B.; Cairns, P.; Nawroz, H.; et al. DPC4 gene in various tumor types. *Cancer Res.* 1996, 56, 2527–2530. [PubMed]

217. Sanders, Y.Y.; Pardo, A.; Selman, M.; Nuovo, G.J.; Tollefsbol, T.O.; Siegal, G.P.; Hagood, J.S. Thy-1 promoter hypermethylation: A novel epigenetic pathogenic mechanism in pulmonary fibrosis. *Am. J. Respir. Cell Mol. Biol.* 2008, 39, 610–618. [CrossRef] [PubMed]

218. Lung, H.L.; Bangararamy, D.K.; Xie, D.; Cheung, A.K.; Cheng, Y.; Kumaran, M.K.; Miller, L.; Liu, E.T.; Guan, X.Y.; Sham, J.S.; et al. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. *Oncoogene* 2005, 24, 6525–6532. [CrossRef]

219. Langevin, S.M.; Kratzke, R.A.; Kelsey, K.T. Epigenetics of lung cancer. *Transl. Res. J. Lab. Clin. Med.* 2015, 165, 74–90. [CrossRef] [PubMed]

220. Huang, S.K.; Scruggs, A.M.; McEachin, R.C.; White, E.S.; Peters-Golden, M. Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. *PLoS ONE* 2014, 9, e107055. [CrossRef]

221. Yang, M.; Shen, H.; Qiu, C.; Ni, Y.; Wang, L.; Dong, W.; Liao, Y.; Du, J. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. *Eur. J. Cancer* 2013, 49, 604–615. [CrossRef]

222. Kolenda, T.; Przybyla, W.; Teresiak, A.; Mackiewicz, A.; Lamperska, K.M. The mystery of let-7d—A small RNA with great power. *Contemp. Oncol.* 2014, 18, 293–301. [CrossRef]

223. Nguyen-Ngoc, T.; Bouchaab, H.; Adjei, A.A.; Peters, S. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. *J. Thorac. Oncol. Off. Publ. Int. Assoc. Stud. Lung Cancer* 2015, 10, 1396–1403. [CrossRef]

224. Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez, F.J.; de Andrade, J.A.; Anstrom, K.J.; King, T.E., Jr.; Lasky, J.A.; et al. Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu, G.; Anstrom, K.J.; King, T.E., Jr.; Lasky, J.A.; et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *N. Engl. J. Med.* 2012, 366, 1968–1977.

225. Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez, F.J.; de Andrade, J.A.; Anstrom, K.J.; King, T.E., Jr.; Raghu, G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *N. Engl. J. Med.* 2014, 370, 2093–2101.

226. Oldham, J.M.; Ma, S.F.; Martinez, F.J.; Anstrom, K.J.; Raghu, G.; Schwartz, D.A.; Valenzi, E.; Witt, L.; Lee, C.; Vij, R.; et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* 2015, 192, 1475–1482. [CrossRef] [PubMed]

227. Sablina, A.A.; Budanov, A.V.; Ilyinskaya, G.V.; Agapova, L.S.; Kravchenko, J.E.; Chumakov, P.M. The antioxidant function of the p53 tumor suppressor. *Nat. Med.* 2005, 11, 1306–1313. [CrossRef] [PubMed]

228. Vafa, O.; Wade, M.; Kern, S.; Beeche, M.; Pandita, T.K.; Hampton, G.M.; Wahl, G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. *Mol. Cell 2002*, 9, 1031–1044. [CrossRef]

229. Sayin, V.I.; Ibrahim, M.X.; Larsson, E.; Nilsson, J.A.; Lindahl, P.; Bengo, M.O. Antioxidants accelerate lung cancer progression in mice. *Sci. Transl. Med.* 2014, 6. [CrossRef] [PubMed]

230. Mitani, Y.; Sato, K.; Muramoto, Y.; Karakawa, T.; Kitamado, M.; Iwanaga, T.; Nabeshima, T.; Maruyama, K.; Nakagawa, K.; Ishida, K.; et al. Superoxide scavenging activity of pirfenidone-iron complex. *Biochem. Biophys. Res. Commun.* 2008, 372, 19–23. [CrossRef] [PubMed]

231. Salazar-Montes, A.; Ruiz-Corro, L.; Lopez-Reyes, A.; Castrejon-Gomez, E.; Armendariz-Borunda, J. Potent antioxidant role of pirfenidone in experimental cirrhosis. *Eur. J. Pharmacol.* 2008, 595, 69–77. [CrossRef] [PubMed]

232. Behr, J.; Bendstrup, E.; Crestani, B.; Gunther, A.; Olschewski, H.; Skold, C.M.; Wells, A.; Wuysts, W.; Koschel, D.; Kreuter, M.; et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: A randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir. Med.* 2016, 4, 445–453. [CrossRef]

233. Hisatomi, K.; Mukae, H.; Sakamoto, N.; Ishimatsu, Y.; Kakugawa, T.; Hara, S.; Fujita, H.; Nakamichi, S.; Oku, H.; Urata, Y.; et al. Pirfenidone inhibits TGF-beta1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. *BMC Pulm. Med.* 2012, 12, 24. [CrossRef]

234. Lin, X.; Yu, M.; Wu, K.; Yuan, H.; Zhong, H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon’s fibroblasts in vitro. *Investig. Ophthalmol. Vis. Sci.* 2009, 50, 3763–3770. [CrossRef] [PubMed]
235. Oku, H.; Shimizu, T.; Kawabata, T.; Nagira, M.; Hikita, I.; Ueyama, A.; Matsushima, S.; Torii, M.; Arimura, A. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. *Eur. J. Pharmacol.* 2008, 590, 400–408. [CrossRef] [PubMed]

236. Choi, K.; Lee, K.; Ryu, S.W.; Im, M.; Kook, K.H.; Choi, C. Pirfenidone inhibits transforming growth factor-betal-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. *Mol. Vis.* 2012, 18, 1010–1020. [PubMed]

237. Miura, Y.; Saito, T.; Tanaka, T.; Takoi, H.; Yatagai, Y.; Inomata, M.; Nei, T.; Saito, Y.; Gemma, A.; Azuma, A. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. *Respir. Investig.* 2018, 56, 72–79. [CrossRef] [PubMed]

238. Xiao, H.; Zhang, G.F.; Liao, X.P.; Li, X.J.; Zhang, J.; Lin, H.; Chen, Z.; Zhang, X. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. *Int. J. Rheum. Dis.* 2018, 21, 477–486. [CrossRef]

239. Iwata, T.; Yoshino, I.; Yoshida, S.; Ikeda, N.; Tsuboi, M.; Asato, Y.; Katakami, N.; Sakamoto, K.; Yamashita, Y.; Okami, J.; et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). *Respir. Res.* 2016, 17, 90. [CrossRef]

240. Mediavilla-Varela, M.; Boateng, K.; Noyes, D.; Antonia, S.J. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. *BMC Cancer* 2016, 16, 176. [CrossRef]

241. Abdollahi, A.; Li, M.; Ping, G.; Plathow, C.; Domhan, S.; Kiessling, F.; Lee, L.B.; McMahon, G.; Grone, H.J.; Lipson, K.E.; et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. *J. Exp. Med.* 2005, 201, 925–935. [CrossRef]

242. Aono, Y.; Nishioka, Y.; Inayama, M.; Ugai, M.; Kishi, J.; Uehara, H.; Izumi, K.; Sone, S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. *Am. J. Respir. Crit. Care Med.* 2005, 171, 1279–1285. [CrossRef]

243. Ishii, Y.; Fujimoto, S.; Fukuda, T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. *Am. J. Respir. Crit. Care Med.* 2006, 174, 550–556. [CrossRef]

244. Li, M.; Abdollahi, A.; Grone, H.J.; Lipson, K.E.; Belka, C.; Huber, P.E. Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. *Radiat. Oncol.* 2009, 4, 66. [CrossRef] [PubMed]

245. Rhee, C.K.; Lee, S.H.; Yoon, H.K.; Kim, S.C.; Lee, S.Y.; Kwon, S.S.; Kim, Y.K.; Kim, K.H.; Kim, T.J.; Kim, J.W. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. *Respir. Int. Rev. Thorac. Dis.* 2011, 82, 273–287. [CrossRef] [PubMed]

246. Adachi, K.; Mizoguchi, K.; Kawarada, S.; Miyoshi, A.; Suzuki, M.; Chiba, S.; Deki, T. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. *J. Toxicol. Sci.* 2010, 35, 503–514. [CrossRef] [PubMed]

247. Wollin, L.; Maillet, I.; Quesniaux, V.; Holweg, A.; Ryffel, B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. *J. Pharmacol. Exp. Ther.* 2014, 349, 209–220. [CrossRef] [PubMed]

248. Arora, A.; Scholar, E.M. Role of tyrosine kinase inhibitors in cancer therapy. *J. Pharmacol. Exp. Ther.* 2005, 315, 971–979. [CrossRef] [PubMed]

249. Daniels, C.E.; Lasky, J.A.; Limper, A.H.; Mieras, K.; Gabor, E.; Schroeder, D.R.; Imatinib, I.P.F.S.I. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. *Am. J. Respir. Crit. Care Med.* 2010, 181, 604–610. [CrossRef]

250. Reck, M.; Kaiser, R.; Mellemgaard, A.; Douillard, J.Y.; Orlov, S.; Krzakowski, M.; von Pawel, J.; Gottfried, M.; Bondarenko, I.; Liao, M.; et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. *Lancet Oncol.* 2014, 15, 143–155. [CrossRef]

251. Malouf, M.A.; Hopkins, P.; Snell, G.; Glenville, A.R.; Everolimus in, I.P.F.S.I. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. *Respirology* 2011, 16, 776–783. [CrossRef]
252. Soria, J.C.; Shepherd, F.A.; Douillard, J.Y.; Wolf, J.; Giaccone, G.; Crino, L.; Cappuzzo, F.; Sharma, S.; Gross, S.I.; Dimitrijevic, S.; et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* 2009, 20, 1674–1681. [CrossRef]

253. An, J.; Xue, Y.; Long, M.; Zhang, G.; Zhang, J.; Su, H. Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. *Oncotarget* 2017, 8, 39230–39240. [CrossRef]

254. Chung, L.Y.; Tang, S.J.; Wu, Y.C.; Sun, G.H.; Liu, H.Y.; Sun, K.H. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with beta-catenin. *Oncotarget* 2015, 6, 4936–4952. [CrossRef] [PubMed]

255. Bai, X.Y.; Zhang, X.C.; Yang, S.Q.; An, S.J.; Chen, Z.H.; Su, J.; Xie, Z.; Gou, L.Y.; Wu, Y.L. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines. *PLoS ONE* 2016, 11, e0149370. [CrossRef] [PubMed]

256. Ide, M.; Tanaka, K.; Sunami, S.; Asoh, T.; Maeyama, T.; Tsuruta, N.; Nakanishi, Y.; Okamoto, I. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. *Thorac. Cancer* 2018, 9, 1519–1521. [CrossRef] [PubMed]

257. Ueda, T.; Aokage, K.; Nishikawa, H.; Neri, S.; Nakamura, H.; Sugano, M.; Tane, K.; Miyoshi, T.; Kojima, M.; Fuji, S.; et al. Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. *J. Cancer Res. Clin. Oncol.* 2018, 144, 835–844. [CrossRef] [PubMed]

258. Chen, X.; Shi, C.; Meng, X.; Zhang, K.; Li, X.; Wang, C.; Xiang, Z.; Hu, K.; Han, X. Inhibition of Wnt/beta-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-beta1 and FGF-2. *Exp. Mol. Pathol.* 2016, 101, 22–30. [CrossRef] [PubMed]

259. Cao, H.; Wang, C.; Chen, X.; Hou, J.; Xiang, Z.; Shen, Y.; Han, X. Inhibition of Wnt/beta-catenin signaling suppresses myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis. *Sci. Rep.* 2018, 8, 13644. [CrossRef] [PubMed]

260. Butts, C.; Socinski, M.A.; Mitchell, P.L.; Thacher, N.; Havel, L.; Krzakowski, M.; Nawrocki, S.; Ciuleanu, T.E.; Bosque, L.; Trigo, J.M.; et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2014, 15, 59–68. [CrossRef]

261. Liu, Y.; Huang, G.; Mo, B.; Wang, C. Artesunate ameliorates lung fibrosis via inhibiting the Notch signaling pathway. *Exp. Ther. Med.* 2017, 14, 561–566. [CrossRef]

262. Xu, L.; Yang, D.; Zhu, S.; Gu, J.; Ding, F.; Bian, W.; Rong, Z.; Shen, C. Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6. *Exp. Lung Res.* 2013, 39, 241–248. [CrossRef]